


Patents Act 1977
(Rule 16)




The
Patent
Office

PLANNING E169188-40 002821
JAN 1996 25.00

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)



The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

SMW/CP5212006

2. Patent application number

(The Patent Office will fill in this part)

19 JAN 1996

9601081.4

3. Full name, address and postcode of the or of each applicant (underline all surnames)

CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED
THE SCIENCE PARK
MELBOURN
ROYSTON
CAMBRIDGESHIRE SG8 6JJ
UNITED KINGDOM

Patents ADP number (if you know it)

5781992002

If the applicant is a corporate body, give the country/state of its incorporation

UNITED KINGDOM

4. Title of the invention

SPECIFIC BINDING MEMBERS FOR HUMAN TRANSFORMING GROWTH FACTOR BETA;
MATERIALS AND METHODS

5. Name of your agent (if you have one)

MEWBURN ELLIS

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

YORK HOUSE
23 KINGSWAY
LONDON WC2B 6HP
UNITED KINGDOM

Patents ADP number (if you know it)

109006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)
GREAT BRITAIN	9520486.3	6 OCTOBER 1995

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

YES

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description 92

Claim(s)

Abstract

Drawing(s) 52

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Mewburn Ellis

Date 19.01.96

MEWBURN ELLIS

12. Name and daytime telephone number of person to contact in the United Kingdom

SEAN M WALTON
0171 240 4405

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered "Yes" Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77



96932730.3

**The
Patent
Office**

The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH

PCT/GB96/02450
PCT/GB96/02450 5

REC'D	30 OCT 1996
WIPO	PCI

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation and Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

21 OCT 1996

PRIORITY DOCUMENT

SPECIFIC BINDING MEMBERS FOR HUMAN TRANSFORMING
GROWTH FACTOR BETA; MATERIALS AND METHODS

This invention relates to specific binding members for human transforming growth factor (TGF) beta and materials and methods relating thereto. In particular, it relates to specific binding members comprising antibody binding domains; for example, human antibodies. Human antibodies against human TGF β may be isolated and utilised in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. The isolation of antiseif antibodies from antibody segment repertoires displayed on phage has been described (A.D.Griffiths et al. EMBO J. 12, 725-734, 1993; A. Nissim et al. EMBO J. 13, 692-698, 1994; A.D. Griffiths et al. 13, 3245-3260, 1994; C.Barbas et al. Proc. Natl. Acad. Sci. USA 90, 10003 10007 1993; WO93/11236).

TGF β is a cytokine known to be involved in many cellular processes such as cell proliferation and differentiation, embryonic development, extracellular matrix formation, bone development, wound healing, hematopoiesis and immune and inflammatory responses (A.B. Roberts & M. Sporn 1990 pp419-472 in Handbook of Experimental Pharmacology eds M.B. Sporn & A.B. Roberts, Springer Heidelberg; J.Massague et al. Annual Rev. Cell Biol. 6, 597-646, 1990).

The accumulation of excessive extra-cellular matrix is associated with various fibrotic diseases.

Thus there is a need to control agents such as TGF β 1 and TGF β 2 to prevent their deleterious effects in such diseases and this is one application of human antibodies to human TGF β .

5 The modulation of immune and inflammatory responses by TGFbetas includes (i) inhibition of proliferation of all T-cell subsets (ii) inhibitory effects on proliferation and function of B lymphocytes (iii) down-regulation of natural-killer cell activity
10 and the T-cell response (iv) regulation of cytokine production by immune cells (v) regulation of macrophage function and (vi) leucocyte recruitment and activation.

 A further application of antibodies to TGF β may
15 be in the treatment of immune/inflammatory diseases such as rheumatoid arthritis, where these functions need to be controlled.

 It is a demanding task to isolate an antibody fragment specific for TGF β of the same species.
20 Animals do not normally produce antibodies to self antigens, a phenomenon called tolerance (G.J. Nossal Science 245, 147-153, 1989). In general, vaccination with a self antigen does not result in production of circulating antibodies. It is therefore difficult to
25 raise human antibodies to human self antigens. There are also in addition, ethical problems in vaccinating humans. In relation to the raising of non-human antibodies specific for TGF β , there are a number of

problems. TGF β is an immunosuppressive molecule and further, there is strong conservation of sequence between human and mouse TGF β molecules. Mouse and human TGF β 1 only differ by one amino acid residue, an alanine (human) to serine (mouse) change at a buried residue (R.Derynck et al. J.Biol. Chem. 261, 4377-4379, 1986). This makes it difficult to raise antibodies in mice against human TGF β . Further, any antibodies raised may only be directed against a restricted set of epitopes.

Polyclonal antibodies binding to human TGF β 1 and human TGF β 2 against both neutralising and non-neutralising epitopes have been raised in rabbit (Danielpour et al. Growth Factors 2 61-71, 1989; A. Roberts et al. Growth Factors 3, 277-286, 1990), chicken (R&D Systems, Minneapolis) and turkey (Danielpour et al. J. Cell Physiol. 138, 79-86, 1989). Peptides representing partial TGF β sequences have also been used as immunogens to raise neutralising polyclonal antisera in rabbits (W.A Border et al. Nature 346, 371-374, 1990; K.C. Flanders Biochemistry 27, 739-746, 1988). In addition there have been limited reports of isolation of mouse monoclonals against TGF β . Following immunisation with bovine TGF β 2 (identical to human TGF β 2), three non-neutralising monoclonal antibodies were isolated that are specific for TGF β 2 and one neutralising antibody that is specific for TGF β 1 and TGF β 2 (J.R. Dasch et

al. J. Immunol. 142, 1536-1541, 1989). In another report, following immunisation with human TGF β 1, neutralising antibodies were isolated which were either specific for TGF β 1 or cross-reacted with TGF β 1, TGF β 2 and TGF β 3 (C. Lucas et al. J. Immunol. 145, 1415-1422, 1990).

This application discloses the first isolation of human antibodies directed against human TGF β 1 and against human TGF β 2.

10 Phage antibody technology (WO92/01047; PCT/GB92/00883; PCT/GB92/01755; WO93/11236) offers the ability to isolate directly human antibodies against human TGF β . In application WO93/11236 the isolation of antiself antibodies from phage display libraries was disclosed and it was suggested that antibodies specific for TGF β could be isolated from phage display libraries.

The present application shows that antibodies of differing specificities for TGF β molecules may be isolated. TGF β 1, TGF β 2 and TGF β 3 are a closely related group of cytokines. They are dimers consisting of two 112 amino acid monomers joined by an interchain disulphide bridge. TGF β 1 differs from TGF β 2 by 27 mainly conservative changes and from TGF β 3 by 22 mainly conservative changes. These differences have been related to the 3D structure (M. Schlunegger & M.G. Grütter Nature 358, 430-434, 1992). The present applicants have isolated antibodies which are

essentially specific for TGF β 1 (very low cross-reactivity with TGF β 2); antibodies which are essentially specific for TGF β 2 (very low cross-reactivity TGF β 1); and antibodies which bind both TGF β 1 and TGF β 2. Hence, these three different types of antibodies, each type with distinctive binding specificities must recognise different epitopes on the TGF β molecules. These antibodies have low cross-reactivity with TGF β 3 as assessed by binding studies using biosensor assays (e.g. BIAcore™), ELISA and radioreceptor assays.

It has further been demonstrated by the applicants that antibodies specific for TGF β can be isolated from libraries derived from different sources of immunoglobulin genes: from repertoires of natural immunoglobulin variable domains; and synthetic repertoires derived from germline V genes combined with synthetic CDR3s. The properties of these antibodies in single chain Fv and whole IgG4 format are described.

As noted above WO93/11236 suggested that human antibodies directed against human TGF β could be isolated from phage display libraries. The applicants show that the phage display libraries from which antiself antibodies were isolated in WO93/11236 may be utilised as a source of human antibodies specific for human TGF β . For instance, in example 1 of the present application, the antibody 1A-E5 specific for TGF β 1 and

the antibodies 2A-H11 and 2A-A9 specific for TGF β 2 were isolated from the 'synthetic library' described in examples 5 to 7 of WO93/11236 and in Nissim et al. (1994; supra). Also, the phage display library
5 derived from peripheral blood lymphocytes (PBLs) of an unimmunised human (examples 1 to 3 of WO93/11236) was the source for the antibody 1B2 specific for TGF β 1. Phage display libraries made subsequently utilising antibody genes derived from human tonsils and bone
10 marrow, have also provided sources of antibodies specific for human TGF β . Thus human TGF β is an example of a human self antigen to which antibodies may be isolated from 'large universal libraries'. Human antibodies against human TGF β with improved
15 properties can be obtained by chain shuffling for instance combining the VH domains of antibodies derived from one library with the VL domains of another library thus expanding the pool of VL partners tested for each VH domain. For instance, the
20 antibodies 6B1, 6AH and 6H1 specific for TGF β 2 utilise the 2A-H11 VH domain isolated from the 'synthetic library' combined with a light chain from the PBL library.

Thus the VH and VL domains of antibodies specific
25 for TGF β can be contributed from phage display libraries derived from rearranged V genes such as those in PBLs, tonsil and bone marrow and from V domains derived from cloned germline V segments

combined with synthetic CDRs. There are also shown to be a diverse range of antibodies which are specific for TGF β 1 or TGF β 2. The antibodies which have been isolated both against TGF β 1 and TGF β 2 have mainly
5 utilised V genes derived from VH germlines of the VH3 family. A wider variety of light chain variable regions have been used, of both the lambda and kappa types.

Individual antibodies which have been isolated
10 have unexpectedly advantageous properties. For example, the antibodies directed against TGF β 2 (6H1, 6A5 and 6B1) have been shown to bind to TGF β 2 with slow off-rates (off-rate constants k_{off} of the order of 10^{-3} s^{-1}) to neutralise TGF β 2 activity in in vitro
15 assays and to be potent in in vivo applications. The properties of these antibodies may make them particularly suitable for therapeutic applications. The fact that these antibodies share the same heavy chain, shows that VH domains can be effective with a
20 number of different light chains, although there may be differences in potency or subtle changes of epitope with different light chains. The antibodies directed against TGF β 1 (1AE5, 1AH6 and 1B2 and their derivatives) also have unexpectedly advantageous
25 properties. Antibody 27C1/10A6 derived from 1B2 by chain shuffling, spiking and conversion into whole antibody IgG4 , has been shown to be potent in an in vitro scarring model. The VH domain of this antibody

was derived by site directed 'spiking' mutagenesis from the parent antibody 7A3. A large number of spiked clones were obtained which show similar properties in in vitro assays. There can be a number of changes in CDR3 of the VH compared to 27C1, for instance, 28A-H11 differs in 7 of the 14 positions, 2 of which are non-conservative changes. Thus there may be up to 50% of the residues in the VH CDR3 changed without affecting binding properties.

10 Antibodies specific for human $TGF\beta 1$ and human $TGF\beta 2$ have been shown to be effective in animal models for the treatment of fibrotic diseases and other diseases such as rheumatoid arthritis where $TGF\beta$ is overexpressed. Antibodies against $TGF\beta$ have been
15 shown to be effective in the treatment of glomerulonephritis (W.A Border et al. Nature 346, 371-374, 1990); neural scarring (A. Logan et al. Eur. J. Neurosci. 6, 355-363, 1994); dermal scarring (M. Shah et al. Lancet 339, 213-214 1992; M. Shah et al. J. Cell
20 Science 107, 1137-1157, 1994; M. Shah et al. 108, 985-1002, 1995); lung fibrosis (S.N. Giri et al. Thorax 48, 959-966, 1993); arterial injury (Y.G. Wolf, L.M. Rasmussen & E. Ruoslahti J. Clin. Invest. 93, 1172-1178, 1994) and rheumatoid arthritis (Wahl et al J.
25 Exp. Medicine 177, 225-230, 1993). It has been suggested that $TGF\beta 3$ acts antagonistically to $TGF\beta 1$ and $TGF\beta 2$ in dermal scarring (M. Shah et al. 1995 supra.). Therefore, antibodies to $TGF\beta 1$ or $TGF\beta 2$ with

apparent low cross-reactivity to TGF β 3, as assessed by binding studies using a biosensor assay (e.g. BIAcore™), ELISA or a radioreceptor assay, as disclosed in this application, that is to say antibodies which bind preferentially to TGF β 1 or TGF β 2 compared with TGF β 3, should be advantageous in this and other conditions such as fibrotic conditions in which it is desirable to counteract the fibrosis promoting effects of TGF β 1 and TGF β 2.

There are likely to be applications further to the above mentioned conditions, as there are several other in vitro models of disease where antibodies against TGF β have shown promise of therapeutic efficacy including antibodies directed against TGF β 2 for the treatment of eye diseases such as proliferative retinopathy (R.A. Pena et al. Invest. Ophthalmology. Vis. Sci. 35, 2804-2808, 1994), retinal detachment and post glaucoma drainage surgery. Other diseases which have potential for treatment with antibodies against TGF β include adult respiratory distress syndrome, cirrhosis of the liver, post myocardial infarction, post angioplasty restenosis, keloid scars and scleroderma.

The use of antibodies against TGF β for the treatment of diseases has been the subject of patent applications for fibrotic disease (WO91/0478); dermal scarring (WO92/17206); macrophage deficiency diseases (PCT/US93/00998); macrophage pathogen infections

(PCT/US93/02017); neural scarring (PCT/US93/03068); vascular disorders (PCT/US93/03795); prevention of cataract (WO95/13827). The human antibodies against human TGF β disclosed in this application should be
5 valuable in these conditions.

The applicants show herein that the human antibodies both against human TGF β 1 and against human TGF β 2 can be effective in the treatment of fibrosis in animal models of neural scarring and
10 glomerulonephritis in either single chain Fv and whole antibody format. This is the first disclosure of the effectiveness of antibodies directed only against TGF β 2 as sole treatment in these indications, although some effectiveness of antibodies against TGF β 2 only
15 has been observed in a lung fibrosis model (Giri et al. Thorax 48, 959-966, 1993 supra). The effectiveness of the human antibodies against human TGF β in treatment of fibrotic disease has been determined by measuring a decrease in the accumulation
20 of components of the extracellular matrix, including fibronectin and laminin in animal models.

TERMINOLOGY

25 *Specific binding member*

This describes a member of a pair of molecules which have binding specificity for one another. The members of a specific binding pair may be naturally

derived or wholly or partially synthetically produced. One member of the pair of molecules has an area on its surface, or a cavity, which specifically binds to and is therefore complementary to a particular spatial and polar organisation of the other member of the pair of molecules. Thus the members of the pair have the property of binding specifically to each other. Examples of types of specific binding pairs are antigen-antibody, biotin-avidin, hormone-hormone receptor, receptor-ligand, enzyme-substrate. This application is concerned with antigen-antibody type reactions.

Antibody

This describes an immunoglobulin whether natural or partly or wholly synthetically produced. The term also covers any polypeptide or protein having a binding domain which is, or is homologous to, an antibody binding domain. These can be derived from natural sources, or they may be partly or wholly synthetically produced. Examples of antibodies are the immunoglobulin isotypes and their isotypic subclasses; fragments which comprise an antigen binding domain such as Fab, scFv, Fv, dAb, Fd; and diabodies.

It is possible to take monoclonal and other antibodies and use techniques of recombinant DNA technology to produce other antibodies or chimeric

molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs), of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB 2188638A or EP-A-239400. A hybridoma or other cell producing an antibody may be subject to genetic mutation or other changes, which may or may not alter the binding specificity of antibodies produced.

As antibodies can be modified in a number of ways, the term "antibody" should be construed as covering any specific binding member or substance having a binding domain with the required specificity. Thus, this term covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or wholly or partially synthetic. Chimeric molecules comprising an immunoglobulin binding domain, or equivalent, fused to another polypeptide are therefore included. Cloning and expression of chimeric antibodies are described in EP-A-0120694 and EP-A-0125023.

It has been shown that fragments of a whole antibody can perform the function of binding antigens. Examples of binding fragments are (i) the Fab fragment

consisting of VL, VH, CL and CH1 domains; (ii) the Fd fragment consisting of the VH and CH1 domains; (iii) the Fv fragment consisting of the VL and VH domains of a single antibody; (iv) the dAb fragment (Ward, E.S. et al., Nature 341, 544-546 (1989)) which consists of a VH domain; (v) isolated CDR regions; (vi) F(ab')₂ fragments, a bivalent fragment comprising two linked Fab fragments (vii) single chain Fv molecules (scFv), wherein a VH domain and a VL domain are linked by a peptide linker which allows the two domains to associate to form an antigen binding site (Bird et al, Science, 242, 423-426, 1988; Huston et al, PNAS USA, 85, 5879-5883, 1988); (viii) bispecific single chain Fv dimers (PCT/US92/09965) and (ix) "diabodies", multivalent or multispecific fragments constructed by gene fusion (WO94/13804; P. Holliger et al Proc. Natl. Acad. Sci. USA 90 6444-6448, 1993).

Diabodies are multimers of polypeptides, each polypeptide comprising a first domain comprising a binding region of an immunoglobulin light chain and a second domain comprising a binding region of an immunoglobulin heavy chain, the two domains being linked (e.g. by a peptide linker) but unable to associate with each other to form an antigen binding site: antigen binding sites are formed by the association of the first domain of one polypeptide within the multimer with the second domain of another polypeptide within the multimer (WO94/13804).

Where bispecific antibodies are to be used, these may be conventional bispecific antibodies, which can be manufactured in a variety of ways (Holliger, P. and Winter G. Current Opinion Biotechnol. 4, 446-449

5 (1993)), eg prepared chemically or from hybrid hybridomas, or may be any of the bispecific antibody fragments mentioned above. It may be preferable to use scFv dimers or diabodies rather than whole antibodies. Diabodies and scFv can be constructed
10 without an Fc region, using only variable domains, potentially reducing the effects of anti-idiotypic reaction. Other forms of bispecific antibodies include the single chain "Janusins" described in Traunecker et al, Embo Journal, 10, 3655-3659, (1991).

15 Bispecific diabodies, as opposed to bispecific whole antibodies, may also be particularly useful because they can be readily constructed and expressed in *E.coli*. Diabodies (and many other polypeptides such as antibody fragments) of appropriate binding
20 specificities can be readily selected using phage display (WO94/13804) from libraries. If one arm of the diabody is to be kept constant, for instance, with a specificity directed against antigen X, then a library can be made where the other arm is varied and
25 an antibody of appropriate specificity selected.

Antigen binding domain

This describes the part of an antibody which

comprises the area which specifically binds to and is complementary to part or all of an antigen. Where an antigen is large, an antibody may only bind to a particular part of the antigen, which part is termed an epitope. An antibody binding domain may be provided by one or more antibody variable domains. Preferably, an antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).

10

Specific

This refers to the situation in which one member of a specific binding pair will not show any significant binding to molecules other than its specific binding partner. The term is also applicable where eg an antigen binding domain is specific for a particular epitope which is carried by a number of antigens, in which case the specific binding member carrying the antigen binding domain will be able to bind to the various antigens carrying the epitope.

15

20

Neutralisation

This refers to the situation in which the binding of a molecule to another molecule results in the abrogation of the biological effector function of the another molecule.

25

Functionally equivalent variant form

This refers to a molecule (the variant) which although having structural differences to another molecule (the parent) retains some significant homology and also at least some of the biological function of the parent molecule, e.g. the ability to bind a particular antigen or epitope. Variants may be in the form of fragments, derivatives or mutants. A variant, derivative or mutant may be obtained by modification of the parent molecule by the addition, deletion, substitution or insertion of one or more amino acids, or by the linkage of another molecule. These changes may be made at the nucleotide or protein level. For example, the encoded polypeptide may be a Fab fragment which is then linked to an Fc tail from another source. Alternatively, a marker such as an enzyme, flouresccin, etc, may be linked.

The present invention provides a specific binding member which comprises a human antibody antigen binding domain specific for TGF β 1 and/or TGF β 2 and which has low cross reactivity with TGF β 3. The cross-reactivity may be as assessed using any or all of the following assays: biosensor (e.g. BIAcore™), ELISA and radioreceptor. The present invention provides specific binding member which comprises a human antibody antigen binding domain specific for TGF β 1 and/or TGF β 2 which binds preferentially to these isoforms compared with TGF β 3.

The TGF β may be human TGF β .

The specific binding member may be in the form of an antibody fragment such as single chain Fv (scFv). Other types of antibody fragments may also be utilised
5 such as Fab, Fab', F(ab')₂, Fabc, Fach or a diabody (G.Winter & C.Milstein Nature 349, 293-299, 1991; WO94/13804). The specific binding member may be in the form of a whole antibody. The whole antibody may be in any of the forms of the antibody isotypes
10 egIgG, IgA, IgE, and IgM and any of the forms of the isotype subclasses eg IgG1 or IgG4.

The specific binding member may also be in the form of an engineered antibody eg bispecific antibody molecules (or fragments such as F(ab')₂) which have
15 one antigen binding arm (ie specific binding domain) against TGF β and another arm against a different specificity. Indeed the specific binding members directed against TGF β 1 and/or TGF β 2 described herein may be combined in a bispecific diabody format. For
20 example the antibodies 31G9 directed against TGF β 1 and 6H1 directed against TGF β 2 may be combined to give a single dimeric molecule with both specificities.

The binding domain may comprise part or all of a VH domain encoded by a germ line gene segment or a re-
25 arranged gene segment. The binding domain may comprise part or all of either a VL kappa domain or a VL lambda domain.

The binding domain may comprise a VH3 gene

sequence of one of the following germ lines; the DP49 germ line; the DP53 germ line; the DP50 germ line; the DP46 germ line; or a re-arranged form thereof.

The specific binding member may neutralise the in vitro and/or in vivo effect of TGF β .

The specific binding member may be a high affinity antibody.

The binding domain may comprise part or all of a VH domain having either an amino acid sequence as shown in Fig 1(a) (i) to (iv) or Fig 1(c) (i) or a functionally equivalent variant form of a said amino acid sequence.

The binding domain may comprise part or all of a VH domain encoded by either a nucleotide sequence as shown in Fig 1(a) (i) to (iv) or Fig 1(c) (i) or a functionally equivalent variant form of a said nucleotide sequence.

The binding domain may comprise part or all of a VL domain having either an amino acid sequence as shown in Fig 1(a) (v) or Fig 1(b) or a functionally equivalent variant form of a said amino acid sequence.

The binding domain may comprise part or all of a VL domain encoded by either a nucleotide sequence as shown in Fig 1(a) (v) or Fig 1(b) or a functionally equivalent variant form of a said nucleotide sequence.

The binding domain may comprise part or all of a VH domain having a variant form of the Fig 1(a) (i) amino acid, the variant form being one of those as

provided by Fig 3.

The binding domain may comprise part or all of a VH domain having either an amino acid sequence as shown in Fig 2(a) (i) to (iii), (v) and (vi) or a
5 functionally equivalent variant form of a said amino acid sequence.

The binding domain may comprise part or all of a VH domain encoded by either a nucleotide sequence as shown in Fig 2(a) (i) to (iii), (v) and (vi) or a
10 functionally equivalent variant form of a said nucleotide sequence.

The binding domain may comprise part or all of a VL domain having either an amino acid sequence as shown in Fig 2(a) (iv) or Fig 2(b) (i) to (v) or a
15 functionally equivalent variant form of a said amino acid sequence.

The binding domain may comprise part or all of a VL domain encoded by either a nucleotide sequence as shown in Fig 2(a) (iv) or Fig 2(b) (i) to (v) or a
20 functionally equivalent variant form of a said nucleotide sequence.

The binding domain may be specific for both TGF β 1 and TGF β 2. The binding domain may be specific for both human TGF β 1 and human TGF β 2. The specific
25 binding member may be in the form of scFv.

The binding domain may comprise part or all of a VL domain having either an amino acid sequence as shown in Fig 4 or a functionally equivalent variant

form of said amino acid sequence. The binding domain may comprise part or all of a VL domain encoded by either the nucleotide sequence as shown in Fig 4 or a functionally equivalent variant form of said
5 nucleotide sequence.

In particular, the binding domain may comprise one or more CDR (complementarity determining region) with an amino acid sequence shown in any of the figures. In a preferred embodiment, the binding
10 domain comprises one or more of the CDRs, CDR1, CDR2 and/or CDR3 shown in the Figures, especially any of those shown in Figure 19. In a preferred embodiment, the binding domain comprises a VH CDR3 sequence as shown, especially as shown in Figure 19. Functionally
15 equivalent variant forms of the CDRs are encompassed by the present invention, in particular variants which differ from the CDR sequences shown by addition, deletion, substitution or insertion of one or more amino acids and which retain ability to bind the
20 antigen and optionally one or more of the preferred characteristics for specific binding members of the present invention as disclosed herein. The specific binding member may comprise all or part of the framework regions shown flanking and between the CDRs
25 in the Figures, especially Figure 19, or different framework regions including modified versions of those shown.

So-called "CDR-grafting" in which one or more CDR

sequences of a first antibody is placed within a framework of sequences not of that antibody, e.g. of another antibody is disclosed in EP-B-0239400.

The present invention also provides a polypeptide
5 with a binding domain specific for TGF β which polypeptide comprises a substantial part or all of either an amino acid sequence as shown in any one of Fig 1(a), Fig 1(b), Fig 1(c), Fig 2(a), Fig 2(b), Fig 4 or a functionally equivalent variant form of a said
10 amino acid sequence. The polypeptide may comprise a substantial part or all of an amino acid sequence which is a functionally equivalent variant form of the Fig 1(a)(i) amino acid sequence, the variant being one of those variants as shown in Fig 3.

15 A specific binding member according to the invention may be one which competes for binding to TGF β 1 and/or TGF β 2 with any specific binding member which both binds TGF β 1 and/or TGF β 2 and comprises part of all of any of the sequences shown in the Figures.
20 Competition between binding members may be assayed easily in vitro, for example by tagging a specific reporter molecule to one binding member which can be detected in the presence of other untagged binding member(s), to enable identification of specific
25 binding members which bind the same epitope or an overlapping epitope.

In addition to an antibody sequence, the specific binding member may comprise other amino acids, e.g.

forming a peptide or polypeptide, or to impart to the molecule another functional characteristic in addition to ability to bind antigen. For example, the specific binding member may comprise a label, an enzyme or a
5 fragment thereof and so on.

The present invention also provides a polynucleotide which codes for a polypeptide with a binding domain specific for TGF β which polynucleotide comprises a substantial part or all of a nucleotide
10 sequence which codes for either an amino acid sequence as shown in any one of Fig 1(a), Fig 1(b), Fig 1(c), Fig 2(a), Fig 2(b), Fig 4 or a functionally equivalent variant form of a said amino acid sequence. The polynucleotide may code for a polypeptide with a
15 binding domain specific for TGF β which polynucleotide comprises a substantial part or all of a nucleotide sequence which codes for an amino acid sequence which is a functionally equivalent variant form of the Fig 1(a)(i) amino acid sequence, the variant being one of
20 those as shown in Fig 3. The polynucleotide may code for a polypeptide with a binding domain specific for TGF β which polynucleotide comprises a substantial part or all of a either a nucleotide sequence as as shown in any one of Fig 1(a), Fig 1(b), Fig 1(c), Fig
25 2(a), Fig 2(b), Fig 4 or a functionally equivalent variant form of said nucleotide sequence. The polynucleotide may code for a polypeptide with a binding domain specific for TGF β which polynucleotide

comprises a substantial part or all a nucleotide sequence which codes for a variant form of the Fig 1(a) (i) amino acid sequence, the variant being one of those as shown in Fig 3.

5 The present invention also provides constructs in the form of plasmids, vectors, transcription or expression cassettes which comprise least one polynucleotide as above.

 The present invention also provides a recombinant
10 host cell which comprises one or more constructs as above.

 A specific binding member according to the present invention may be made by expression from encoding nucleic acid. Nucleic acid encoding any
15 specific binding member as provided itself forms an aspect of the present invention, as does a method of production of the specific binding member which method comprises expression from encoding nucleic acid therefor. Expression may conveniently be achieved by
20 culturing under appropriate conditions recombinant host cells containing the nucleic acid.

 The nucleic acid may encode any of the amino acid sequences shown in any of the Figures, or any functionally equivalent form. The nucleotide
25 sequences employed may be any of those shown in any of the Figures, or may be a variant, allele or derivative thereof. Changes may be made at the nucleotide level by addition, substitution, deletion or insertion of

one or more nucleotides, which changes may or may not be reflected at the amino acid level, dependent on the degeneracy of the genetic code.

Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host cells include bacteria, mammalian cells, yeast and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells and many others. A common, preferred bacterial host is *E. coli*.

The expression of antibodies and antibody fragments in prokaryotic cells such as *E. coli* is well established in the art. For a review, see for example Plückthun, A. *Bio/Technology* 9: 545-551 (1991). Expression in eukaryotic cells in culture is also available to those skilled in the art as an option for production of a specific binding member, see for recent reviews, for example Reff, M.E. (1993) *Curr. Opinion Biotech.* 4: 573-576; Trill J.J. et al. (1995) *Curr. Opinion Biotech* 6: 553-560.

Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids, viral e.g. phage, or phagemid, as

appropriate. For further details see, for example, *Molecular Cloning: a Laboratory Manual*: 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press. Many known techniques and protocols for
5 manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Short Protocols in Molecular Biology*, Second
10 Edition, Ausubel et al. eds., John Wiley & Sons, 1992. The disclosures of Sambrook et al. and Ausubel et al. are incorporated herein by reference.

Thus, a further aspect of the present invention provides a host cell containing nucleic acid as
15 disclosed herein. A still further aspect provides a method comprising introducing such nucleic acid into a host cell. The introduction may employ any available technique. For eukaryotic cells, suitable techniques may include calcium phosphate transfection, DEAR-
20 Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g. vaccinia or, for insect cells, baculovirus. For bacterial cells, suitable techniques may include calcium chloride transformation,
25 electroporation and transfection using bacteriophage.

The introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells under conditions for expression

of the gene.

In one embodiment, the nucleic acid of the invention is integrated into the genome (e.g. chromosome) of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques.

The present invention also provides a method which comprises using a construct as stated above in an expression system in order to express a specific binding member or polypeptide as above.

Following production of a specific binding member it may be used for example in any of the manners disclosed herein, such as in the formulation of a pharmaceutical or a diagnostic product, such as a kit comprising in addition to the specific binding member one or more reagents for determining binding of the member to cells, as discussed.

The present invention also provides pharmaceuticals which comprise a specific binding member as above, optionally with one or more excipients.

The present invention also provides the use of a specific binding member as above in the preparation of a medicament to treat a condition in which it is advantageous to counteract the fibrosis promoting effects of TGF β . The condition may be a fibrotic condition characterized by an accumulation in a tissue

of components of the extracellular matrix. The components of the extracellular matrix may be fibronectin or laminin.

The condition may be selected from the group
5 consisting of:

glomerulonephritis
neural scarring
dermal scarring
lung fibrosis
10 arterial injury
proliferative retinopathy
retinal detachment
adult respiratory distress syndrome
liver cirrhosis
15 post myocardial infarction
post angioplasty restenosis
keloid scarring
scleroderma
vascular disorders
20 cataract
glaucoma.

The condition may be neural scarring or glomerulonephritis.

25 The present invention also provides the use of a specific binding member as above, in the preparation of a medicament to treat an immune/inflammatory disease condition in which it is advantageous to

counteract the effects of $\text{TGF}\beta$. Illustrative conditions are rheumatoid arthritis, macrophage deficiency disease and macrophage pathogen infection.

The present invention also provides a method
5 which comprises administering to a patient a therapeutically effective amount of a specific binding member as above in order to treat a condition in which it is advantageous to counteract the fibrosis promoting effects of $\text{TGF}\beta$. Fibrotic conditions are
10 listed above.

The present invention also provides a method which comprises administering to a patient a prophylactically effective amount of a specific binding member as above in order to prevent a
15 condition in which it is advantageous to prevent the fibrosis promoting effects of $\text{TGF}\beta$. Fibrotic conditions are listed above.

The present invention also provides methods which comprise administering to patients prophylactically
20 and/or therapeutically effective amounts of a specific binding member as above in order to prevent or treat an immune/inflammatory disease condition in which it is advantageous to counteract the effects of $\text{TGF}\beta$. Illustrative conditions are stated above.

25 Thus, various aspects of the invention provide methods of treatment comprising administration of a specific binding member as provided, pharmaceutical compositions comprising such a specific binding

member, and use of such a specific binding member in the manufacture of a medicament for administration, for example in a method of making a medicament or pharmaceutical composition comprising formulating the
5 specific binding member with a pharmaceutically acceptable excipient.

In accordance with the present invention, compositions provided may be administered to individuals. Administration is preferably in a
10 "therapeutically effective amount", this being sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature
15 and severity of what is being treated. Prescription of treatment, eg decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors. Appropriate doses of antibody are well known in the art; see Ledermann J.A. et al.
20 (1991) Int J. Cancer 47: 659-664; Bagshawe K.D. et al. (1991) Antibody, Immunoconjugates and Radiopharmaceuticals 4: 915-922.

A composition may be administered alone or in combination with other treatments, either
25 simultaneously or sequentially dependent upon the condition to be treated.

Pharmaceutical compositions according to the present invention, and for use in accordance with the

present invention, may comprise, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials
5 should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. intravenous.

10 Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may comprise a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such
15 as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

20 For intravenous, injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are
25 well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers,

antioxidants and/or other additives may be included,
as required.

Further aspects of the invention and embodiments
5 will be apparent to those skilled in the art. In
order that the present invention is fully understood,
the following examples are provided by way of
exemplification only and not by way of limitation.

Reference is made to the following figures.

10

Figure 1 shows the DNA and protein sequences of
antibodies specific for TGF β 1.

Figure 2 shows the DNA and protein sequences of
antibodies specific for TGF β 2.

15 Figure 3 shows the protein sequences of VH CDR3
of clones derived from 1B2 by 'spiking' mutagenesis.

Figure 4 shows the DNA and protein sequence of
the VH and VL domains of VT37.

20 Figure 5 shows the DNA sequence in the region of
the heavy chain VH leader from the vector vhcassette2.

Figure 6 shows a map of the vector pG4D100.

Figure 7 shows the DNA sequence in the region of
the light chain VL leader for the vector vlcassettel.

Figure 8 shows a map of the vector pLN10.

25 Figure 9 shows a map of the vector pKN100.

Figure 10 shows the neutralisation of TGF β 2
activity by whole IgG4 antibodies in an assay using
proliferation of the erythroleukaemia cell line, TF1.

Figure 11 shows the neutralisation of TGF β 2 activity by single chain Fv antibodies in an assay using proliferation of the erythroleukaemia cell line, TF1.

5 Figure 12 shows the effect of treatment of animals with antibodies on neural scarring as measured by the deposition of (a) fibronectin and (b) laminin detected using integrated fluorescence intensity. The graphs show scatter plots of individual animal data
10 points. The bar graph shows the mean of the group.

Figure 13 shows the results of an ELISA to measure the cross-reactivity of the antibodies 6B1 IgG4 and 6A5 IgG4 with TGF β isoforms and non-specific antigens.

15 Figure 14 shows the amount of urinary protein in 24h measured for rat groups A to E in the experimental glomerulonephritis model.

Figure 15 shows the periodic acid Schiff matrix score (derived by measurement of the amount of
20 staining) for rat groups A to E in the experimental glomerulonephritis model.

Figure 16 shows % neutralisation of TGF- β 2 anti-proliferative effect on TF1 cells by whole antibodies, 6H1 IgG4, 6B1 IgG2 and the mouse monoclonal from
25 Genzyme, at various concentrations (nM IgG).

Figure 17 shows % neutralisation of TGF- β 1 anti-proliferative effect on TF1 cells by whole antibodies, 6H1 IgG4, 6B1 IgG2 and the mouse monoclonal

from Genzyme, at various concentrations (nM IgG).

Figure 18 shows % neutralisation of TGF- β 3 anti-proliferative effect on TF1 cells by whole antibodies, 6H1 IgG4, 6B1 IgG2 and the mouse monoclonal from

5 Genzyme, at various concentrations (nM IgG).

Figure 19 shows sequences of regions of antibodies directed against TGF β 2 showing CDR sequences in italics: 2A-H11 VH (also known as 6H1 VH); 6B1 VL; 6A5 VL and 6H1 VL.

10

All documents mentioned herein are incorporated by reference.

List of Examples

15

Example 1 - Isolation of antibodies specific for TGF β 1, antibodies specific for TGF β 2 and antibodies specific for TGF β 1 and TGF β 2.

20 Example 2 - Construction of cell lines expressing whole antibodies.

Example 3 - Neutralisation of TGF β activity by antibodies assessed using in vitro assays.

25

Example 4 - Inhibition by antibodies of TGF β binding to receptors.

Example 5 - Prevention of neural scarring using antibodies against TGF β .

5 Example 6 - Prevention of glomerulonephritis using antibodies against TGF β .

10 Example 7 - Neutralisation by antibodies directed against TGF β 2 of the inhibitory effect of TGF β isoforms on cells proliferation.

Example 8 - Inhibition by antibodies directed against TGF β 2 of binding of other TGF β isoforms to receptors measured in a radioreceptor assay.

15

Example 1 Isolation and characterisation of antibodies binding to TGF β 1 and TGF β 2

20 1. Identification and Characterization of Antibodies to Human TGF β -1 by Selection of Naive and Synthetic Phage Antibody Repertoires

Antibody repertoires

The following antibody repertoires were used:

25

1. Peripheral blood lymphocyte (PBL) library derived from unimmunized human (Marks, J. D., Hoogenboom, H. R. Bonnett, T. P., McCafferty, J., Griffiths, A. D. &

Winter, G. (1991) J. Mol. Biol. 222, 581-597)

2. Synthetic library (Nissim, A., Hoogenboom, H. R.,

Tomlinson, I. M., Flynn, G., Midgley, C., Lane, D. and

- 5 Winter, G. (1994) EMBO J. 13, 692-698) derived from
cloned human germline VH genes and synthetic CDR3s
with a fixed light chain

3. Tonsil library derived from the tonsils of

- 10 unimmunised humans. Tonsil B cells were isolated from
freshly removed (processed within 2 hours) whole
tonsils provided by Addenbrookes Hospital, Hills Road,
Cambridge, U.K. Each tonsil was processed as follows.
Tonsils were placed in a petri dish containing 5ml of
15 PBS and macerated with a scalpel blade to release the
cells. The suspension was transferred to a fresh tube
and large debris allowed to sediment under gravity for
5 minutes. The cell suspension was then overlaid onto
10mls of Lymphoprep in a 50 ml polypropylene tube
20 (Falcon) and centrifuged at 1000xg 20 minutes at room
temperature (no brake) and cells at the interface.
harvested with a glass pipette. These were diluted to
a final volume of 50 ml in RPMI medium at 37° C and
centrifuged at 500xg for 15 minutes at room
25 temperature. The supernatant was aspirated and the the
cells washed another two times with RPMI.

Polyadenylated RNA was prepared from pelleted
cells using the "Quickprep™ mRNA Kit" (Pharmacia

Biotech, Milton Keynes, U.K.). The entire output of cells from one tonsil (ca. 1×10^6 cells) was processed using one Oligo(dT)-Cellulose Spun column and processed exactly as described in the accompanying
 5 protocol. MRNA was ethanol precipitated as described and resuspended in 40ml RNase free water.

The cDNA synthesis reaction was set up using the "First-Strand cDNA Synthesis Kit (Pharmacia Biotech, Milton Keynes, U.K.) as follows:

10 RNA- 20 μ l (heated to 67 $^{\circ}$ C 10 minutes before use)

1st strand buffer- 11 μ l.

DTT solution 1 μ l

pd(N)₆ primer 1 μ l

15 After gentle mixing, the reaction was incubated at 37 $^{\circ}$ C for 1 hour.

Human VH genes were amplified from tonsil cDNA using the nine family-based back primers (VH 1b/7a -6a back Sfi , which introduce a Sfi I site at the 5'-end,
 20 Table 1) together with an equimolar mixture of the four JH forward primers (JH 1-2, 3, 4-5, 6, for; Marks et al., 1991 supra). Thus, nine primary PCR amplifications were performed. Each reaction mixture (50 μ l) comprised 2 μ l cDNA template, 25 pmol back
 25 primer, 25 pmol forward primers, 250 μ M dNTPs, 1.5 mM MgCl₂, 50 mM KCl, 10 mM Tris-HCL pH 8.3 and 2.5 u of Taq polymerase (Boehringer). The reaction mixture was overlaid with mineral (paraffin) oil and was cycled 30

times (94 °C for 1 min, 55 °C for 1 min, 72 °C for 1 min) using a Techne thermal cycler. The products were purified on a 1% (w/v) agarose gel, isolated from the gel using "Geneclean" (Bio 101 Inc.) and resuspended in 15 µl of water. The amplified VH genes were recombined with human VL genes derived from PBLs (Marks et al., 1991 supra) together with the (Gly₄, Ser)₃ linker (Huston, J.S., et al. 1988 Proc Natl Acad Sci U S A. 85: 5879-83) by PCR assembly (Marks et al, 1991 supra). The VH-linker-VL antibody constructs were cloned into the SfiI and NotI sites of the phagemid vector, pCANTAB6 (McCafferty, J., et al. 1994 Appl. Biochem. Biotech. 47: 157 - 173) to give a library of 6 x 10⁷ clones.

15

4. Large single chain Fv library derived from lymphoid tissues including tonsil, bone marrow and peripheral blood lymphocytes.

20

Polyadenylated RNA was prepared from the B-cells of various lymphoid tissues of 43 non-immunised donors using the "Quickprep mRNA Kit" (Pharmacia). First-strand cDNA was synthesized from mRNA using a "First-strand cDNA synthesis" kit (Pharmacia) using random hexamers to prime synthesis. V-genes were amplified using family-specific primers for VH, Vκ and Vλ genes as previously described (Marks et al., supra) and subsequently recombined together with the (Gly₄,

Ser), scFv linker by PCR assembly. The VH-linker-VL antibody constructs were cloned into the Sfi I and Not I sites of the phagemid vector, pCANTAB 6. Ligation, electroporation and plating out of the cells was as described previously (Marks et al, 1991 supra). The library was made ca. 1000x larger than that described previously by bulking up the amounts of vector and insert used and by performing multiple electroporations. This generated a scFv repertoire that was calculated to have ca. 1.3×10^{10} individual recombinants which by Bst NI fingerprinting were shown to be extremely diverse.

a. Induction of phage antibody libraries

The four different phage antibody repertoires above were selected for antibodies to TGF β -1. The VH synthetic (Nissim et al., 1994 supra), tonsil, 'large' scFv and PBL (Marks et al., 1991 supra) repertoires were each treated as follows in order to rescue phagemid particles. 500 ml prewarmed (37 °C) 2YT_{AG} (2YT media supplemented with 100 μ g/ml ampicillin and 2 % glucose) in a 2 l conical flask was inoculated with approximately 3×10^{10} cells from a glycerol stock (-70 °C) culture of the appropriate library. The culture was grown at 37 °C with good aeration until the OD_{600nm} reached 0.7 (approximately 2 hours). M13K07 helper phage (Stratagene) was added to the culture to a multiplicity of infection (moi) of

approximately 10 (assuming that an OD_{600nm} of 1 is equivalent to 5×10^8 cells per ml of culture). The culture was incubated stationary at $37^\circ C$ for 15 minutes followed by 45 minutes with light aeration (200 rpm) at the same temperature. The culture was centrifuged and the supernatant drained from the cell pellet. The cells were resuspended in 500 ml 2YTAK (2YT media supplemented with 100 $\mu g/ml$ ampicillin and 50 $\mu g/ml$ kanamycin), and the culture incubated overnight at $30^\circ C$ with good aeration (300 rpm). Phage particles were purified and concentrated by three polyethylene glycol (PEG) precipitations (Sambrook, J., Fritsch, E.F., & Maniatis, T. (1990). Molecular Cloning - A Laboratory Manual. Cold Spring Harbour, New York) and resuspended in PBS to 10^{12} transducing units (tu)/ml (ampicillin resistant clones).

b. Panning of phage antibody library on TGF β -1

Phage induced from the four repertoires were each separately panned on TGF β -1. A 75mm x 12mm immuno tube (Nunc; Maxisorp) was coated with 2 ml of recombinant human TGF β -1 (0.5 $\mu g/ml$, Genzyme) in PBS overnight at $4^\circ C$. After washing 3 times with PBS, the tube was filled with 3%MPBS (3 % 'Marvel' skimmed milk powder, 1x PBS) and incubated for 2 hours at $37^\circ C$ for blocking. The wash was repeated, phagemid particles (10^{13} tu) in 2 ml of 3% MPBS were added and the tube

incubated stationary at 37 °C for 1 hour. The tube was washed 20 times with PBST(0.1%), then 20 times with PBS. Bound phage particles were eluted from the tube by adding 2 ml of 100mM-triethylamine, and
5 incubating the tube stationary at room temperature for 10 minutes. The eluted material was immediately neutralised by pipetting into a tube containing 1 ml 1M-Tris.HCl (pH7.4). Phage were stored at 4 °C. 1.5 ml of the eluted phage were used to infect 20 ml of
10 logarithmically growing E. coli TG1 (Gibson, T.J. (1984). PhD thesis. University of Cambridge, UK.)). Infected cells were grown for 1 hour at 37 °C with light aeration in 2YT broth, and then plated on 2YTAG medium in 243mm x 243mm dishes (Nunc). Plates were
15 incubated overnight at 30 °C. Colonies were scraped off the plates into 10 ml of 2YT broth and 15 % (v/v) glycerol added for storage at -70 °C.

Glycerol stock cultures from the first round of panning of each of the four repertoires on TGFβ-1 were
20 each rescued using helper phage to derive phagemid particles for the second round of panning. 250 µl of glycerol stock was used to inoculate 50 ml 2YTAG broth, and incubated in a 250 mL conical flask at 37 °C with good aeration until the OD_{600nm} reached 0.7
25 (approximately 2 hours). M13K07 helper phage (moi=10) was added to the culture which was then incubated stationary at 37 °C for 15 minutes followed by 45 minutes with light aeration (200 rpm) at the same

temperature. The culture was centrifuged and the supernatant drained from the cell pellet. The cells were resuspended in 50 ml prewarmed 2YTAK, and the culture incubated overnight at 30 °C with good
5 aeration. Phage particles were purified and concentrated by PEG precipitation (Sambrook et al., 1990 supra) and resuspended in PBS to 1013 tu/ml.

Phage induced from the first round of panning of each of the three repertoires, was selected a second
10 time essentially as described above except that the panning tube was coated with only 1 ml of TGFβ-1 (0.5ug/ml, Genzyme), and the volume of phage added to the tube similarly reduced. After extensive washing, bound phage were eluted from the tube using 1 ml of
15 100 mM-triethylamine, and neutralised by the addition of 0.5 ml 1M-Tris.HCl (pH7.4) as earlier described. The process of phage growth and panning was repeated over a third and a fourth round of selection.

20 c. Growth of single selected clones for immunoassay

Individual colonies from the third and fourth round selections were used to inoculate 100 µl 2YTAK into individual wells of 96 well tissue culture plates (Corning). Plates were incubated at 30 °C overnight
25 with moderate shaking (200 rpm). Glycerol to 15 % was added to each well and these master plates stored at -70 °C until ready for analysis.

d. ELISA to identify anti-TGF β -1 scFv

Clones specific for TGF β -1 were identified by ELISA, using scFv displayed on phage or soluble scFv.

5 i. Phage ELISA

Cells from the master plates were used to inoculate fresh 96 well tissue culture plates containing 100 μ l 2YTAG per well. These plates were incubated at 37 $^{\circ}$ C for 6-8 hours or until the cells in
10 the wells were growing logarithmically (OD600 0.2-1.0). M13K07 was added to each well to an moi of 10 and incubated stationary for 15 min then 45 min with gentle shaking (100 rpm), both at 37 $^{\circ}$ C. The plates were centrifuged at 2000 rpm for 10 min and the
15 supernatant eluted. Each cell pellet was resuspended in 100 μ l 2YTAK and incubated at 30 $^{\circ}$ C overnight.

Each plate was centrifuged at 2000 rpm and the 100 μ l supernatant from each well recovered and blocked in 20 μ l 18% M6PBS (18 % skimmed milk powder, 6
20 x PBS), stationary at room temperature for 1 hour.

Meanwhile, flexible microtitre plates which had been blocked overnight stationary at 4 $^{\circ}$ C with either 50 μ l 0.2 μ g/ml TGF β -1 in PBS or 50 μ l PBS alone (giving an uncoated control plate), were washed 3 times in PBS
25 and blocked for 2 h stationary at 37 $^{\circ}$ C in 3MPBS.

These plates were then washed three times with PBS and 50 μ l preblocked phage added to each well of both the TGF β -1-coated or uncoated plate. The plates were

incubated stationary at 37 °C for 1 h after which the phage were poured off. The plates were washed by incubating for 2 min in PBST three times followed by incubating for 2min in PBS three times, all at room temperature.

To each well of both the TGF β -1-coated and the uncoated plate, 50 μ l of a 1 in 10,000 dilution of sheep anti-fd antibody (Pharmacia) in 3MPBS was added and the plates incubated at 37 °C stationary for 1 h.

Each plate was washed as described above and 50 μ l of a 1 in 5,000 dilution donkey anti-sheep alkaline phosphatase conjugate (Sigma) in 3MPBS added and incubated stationary at 37 °C for 1 h. Plates were washed as described as above followed by two rinses in 0.9% NaCl. Alkaline phosphatase activity was visualised using either the chromagenic substrate pNPP (Sigma) or the Ampak system (Dako). The absorbance signal generated by each clone was assessed by measuring the optical density at either 405 nm (pNPP) or 492 nm (Ampak) using a microtitre plate reader. Clones were chosen for further analysis if the ELISA signal generated on the TGF β -1-coated plate was at least double that on the uncoated plate.

ii. Soluble ELISA

Cells from the master plates were used to inoculate fresh 96 well tissue culture plates containing 100 μ l 2YTAG per well. These plates were

incubated at 30 °C for 8 hours then centrifuged at 2000 rpm for 10 min and the supernatant eluted. Each cell pellet was resuspended in 100 µl 2YTA (2YT media supplemented with 100ug/ml ampicillin) containing 10 mM IPTG (isopropyl-B-D-thiogalactopyranoside) and incubated at 30 °C overnight.

Each plate was centrifuged at 2000 rpm and the 100 µl supernatant from each well recovered and blocked in 20 µl 18% M6PBS stationary at room temperature for 1 hour. Meanwhile, flexible microtitre plates which had been blocked overnight stationary at 4 °C with either 50 µl 0.2 µg/ml TGFβ-1 in PBS or 50 µl PBS alone, were washed 3 times in PBS and blocked for 2 h stationary at 37 °C in 3% MPBS. These plates were then washed three times with PBS and 50 µl preblocked soluble scFv added to each well of both the TGFβ-1-coated or uncoated plate. The plates were incubated stationary at 37 °C for 1 h after which the scFv solutions were poured off. The plates were washed by incubating for 2 min in PBST (PBS containing 1% Tween) three times followed by incubating for 2 min in PBS three times, all at room temperature.

To each well of both the TGFβ-1-coated and the uncoated plate, 50 µl of a 1 in 200 dilution of the anti-myc tag murine antibody 9E10 (Munro, S. & Pelham, H.R.B. (1986) Cell 46, 291-300) in 3MPBS was added and the plates incubated at 37 °C stationary for 1 h.

Each plate was washed as described above and 50 μ l of a 1 in 5,000 dilution goat anti-mouse alkaline phosphatase conjugate (Pierce) in 3MPBS added and incubated stationary at 37 $^{\circ}$ C for 1 h. Plates were washed as described above followed by two rinses in 0.9% NaCl. Alkaline phosphatase activity was visualised using either the chromagenic substrate pNPP (Sigma) or the Ampak system (Dako). The absorbance signal generated by each clone was assessed by measuring the optical density at either 405 nm (pNPP) or 492 nm (Ampak) using a microtitre plate reader. Clones were chosen for further analysis if the ELISA signal generated on the TGF β -1-coated plate was at least double that on the uncoated plate.

15

iii. Specificity ELISA

Clones identified as binding TGF β -1 rather than uncoated well, as described above, were further analysed for fine specificity. Specificity ELISA's were carried out using scFv either displayed on phage or in solution as described above, except that 5 ml of media in 50 ml Falcon tubes were inoculated with each clone and grown to generate the phage or soluble scFv used in the ELISA. Microtitre plate wells were coated with 50 μ l of either 0.2 μ g/ml TGF β -1, 0.2 μ g/ml TGF β -2, 10 μ g/ml bovine serum albumin (BSA) or PBS (the uncoated well). After preblocking both the phage (or soluble scFv) and the microtitre plates, 50 μ l

blocked phage (or soluble scFv) from each clone was added to a well coated with either TGF β -1, TGF β -2, BSA or an uncoated well. As above, alkaline phosphatase activity was visualised using either the chromagenic substrate pNPP (Sigma) or the Ampak system (Dako). Clones were considered to be specific for TGF β -1 if the ELISA signal generated in the TGF β -1 coated well was at least five-fold greater than the signal on either TGF β -2, BSA or an uncoated well.

10

iv. Specificity determination by BIAcore™

The antibodies were also shown to be specific for TGF β 1 compared to TGF β 2 (obtained from R&D Systems Abingdon) by relative binding to the BIAcore™ sensor chips coated with the appropriate antigen. TGF β 1 and TGF β 2 were immobilised by amine coupling to Biosensor CM5 sensor chips (Pharmacia) according to the manufacturers instructions. Single chain Fv fragments (35 μ l; purified by immobilized metal affinity chromatography as described in example 4) were injected over the immobilized antigen at a flow rate of 5 μ l/min. The amount of TGF β bound was assessed as the total increase in resonance units (RUs) over this period. For 31G9 scFv an increase of 1059RUs was found with a TGF β 1 chip and 72 RUs was found with a TGF β 2 chip. Thus binding is much stronger to TGF β 1 than TGF β 2.

e. Sequencing of TGF β 1-Specific ScFv Antibodies

The nucleotide sequence of the TGF β -1 specific antibodies was determined by first using vector-specific primers to amplify the inserted DNA from each clone. Cells from an individual colony on a 2YTAG agar plate were used as the template for a polymerase chain reaction (PCR) amplification of the inserted DNA using the primers pUC19reverse and fdtetseq (Table 1). Amplification conditions consisted of 30 cycles of 94 °C for 1 min, 55 °C for 1 min and 72 °C for 2 min, followed by 10 min at 72 °C. The PCR products were purified using a PCR Clean-up Kit (Promega) in to a final volume of 50 μ l H₂O. Between 2 and 5 μ l of each insert preparation was used as the template for sequencing using the Tag Dye-terminator cycle sequencing system (Applied Biosystems). The primers mycseq10 and PCR-L-Link were used to sequence the light chain of each clone and PCR-H-Link and pUC19reverse to sequence the heavy chain (Table 1)

f. Sequence and Source of the Initial TGF β -1-Specific ScFv Antibodies

Four different TGF β -1 specific antibodies were isolated from the selections using the four libraries described above. Each clone name, its origin and its heavy and light chain germline is given below. The complete sequence of each VH domain gene is given in

figure 1(a), together with the VL domain gene; from scFv 31G9.

CLONE	LIBRARY SOURCE	VH GERMLINE	VL ISOTYPE
1-B2	PBL	VH3 DP49	VKappa
1A-E5	Synthetic VH	VH3 DP53	VLambda
1A-H6	Tonsil	VH3 DP50	VLambda
31-G9	large scFv	VH3 DP49	VLambda

10

Thus these initial isolates were obtained from libraries derived from different sources-both natural V genes of unimmunised humans and synthetic libraries from cloned germline V genes together with synthetic

15 CDRs.

2. Affinity Maturation of the Initial TGF β -1-Specific ScFv Antibodies

20 a. Light Chain Shuffling of the TGF β -1-Specific ScFv Antibody 1-B2

i. Construction of Repertoires

The heavy chain of clone 1-B2 was recombined with
 25 the complete repertoire of light chains derived from the PBL and large (tonsil-derived) scFv repertoires. The 1-B2 heavy chain was amplified by PCR using the primers HuJh4-5For (Table 1) and pUC19reverse.

Amplification conditions consisted of 30 cycles of 94 °C for 1 min, 55 °C for 1 min and 72 °C for 1min, followed by 10 min at 72 °C. The PCR product was separated through a 1% agarose-TAE gel, the band representing the amplified VH excised, and eluted from the agarose gel using the Geneclean Kit (Bio 101).

The PBL and tonsil light chains were amplified by PCR using the primers fdtetseq and a mix of RL1, 2 & 3 (Table 1). Amplification conditions consisted of 30 cycles of 94 °C for 1 min, 55 °C for 1 min and 72 °C for 1min, followed by 10 min at 72 °C. The PCR product was separated through a 1% agarose-TAE gel, the band representing the amplified VL excised, and eluted from the agarose gel using the Geneclean Kit (Bio 101).

Approximately 50 ng amplified 1-B2 heavy chain and 50 ng of either amplified PBL-derived or amplified tonsil-derived light chains were combined and precipitated with sodium acetate and ethanol using 25 µg glycogen as a carrier. The precipitated DNA was pelleted by centrifugation at 13,000 rpm in a microfuge, air dried and resuspended in 26 µl H₂O. This was used in an assembly amplification after the addition of reaction buffer to 1X, dNTP's to 200 nM and 5 units Taq polymerase. Amplification conditions consisted of 20 cycles of 94 °C for 1 min, 60 °C for 1 min and 72 °C for 1min 30 s, followed by 10 min at 72 °C. 10 µl of each assembly was used as the template

in a 'pull-through' amplification with the primers fdtetseq and pUC19reverse. Amplification conditions consisted of 25 cycles of 94 °C for 1 min, 60 °C for 1 min and 72 °C for 1 min 30 s, followed by 10 min at 72 °C.

The pull-through amplification product was separated through 1% agarose-TAE and the band representing the pull-through VH-VL excised and eluted using the Geneclean Kit. This was digested with the restriction endonucleases Sfi I and Not I (NEB) and ligated (Amersham ligation system) into the phagemid vector pCantab 6, previously digested with Sfi I and Not I. The ligation product was used to transform electrocompetent TG1 cells, plated out on 2YTAG plates and incubated overnight at 30 °C. Approximately 1×10^5 individual clones were generated from the light chain-shuffle of the 1-B2 heavy chain with the PBL-derived light chains and approximately 1×10^6 for the shuffle with the tonsil-derived light chains.

20

ii. Selection of Light Chain Shuffle Repertoires

The two light chain-shuffle repertoires were selected for TGF β -1-specific antibodies. Phagemid particles were recovered from each repertoire as described earlier for the initial libraries. Recovered phage were preblocked for 1 h in a final volume of 100 μ l 3MPBS. Approximately 10^{11} tu phage were used in the first round selection and between 10^9

and 10^{10} for subsequent selections. For the first round selections, biotinylated TGF β 1 to a final concentration of 100 nM was added to the preblocked phage and incubated stationary at 37°C for 1h.

- 5 For each selection, 100 μ l Dynabeads suspension (Dyna) was separated on a magnet and the beads recovered and preblocked for 2 h in 1 ml 3MPBS. The beads were recovered on a magnet and resuspended in the phagemid/biotinylated TGF β -1 mixture and incubated
- 10 at room temperature for 15 min while being turned end-over-end. The beads were captured on a magnet and washed four times with PBST followed by three washes in PBS. After each wash, the beads were captured on a magnet and resuspended in the next wash. Finally,
- 15 half of the beads were resuspended in 10 μ l 50 mM DTT (the other half of the beads stored at 4 °C as a back-up) and incubated at room temperature for 5 min. The whole bead suspension was then used to infect 5 ml logarithmically-growing TG1 cells. This was incubated
- 20 at 37 °C, stationary for 15 min then with moderate shaking for 45 min, plated on 2YTAG plates and incubated overnight at 30 °C.

Colonies were scraped off the plates into 10 ml of 2YT broth and 15 % (v/v) glycerol added for storage

25 at -70 °C. A 250 μ l aliquot of each plate scrape was used to inoculate 2YTAG and phagemid particles rescued as described earlier. For each repertoire, three rounds of selection using biotinylated TGF β -1 was

performed, essentially identical to the first round selection described above. All selections were at 100 nM TGF β -1 except for the third round selection of the tonsil-derived light chain repertoire where the concentration of biotinylated TGF β -1 in the selection was reduced to 50 nM.

iii. Identification of TGF β -1-Specific ScFv Antibodies from Light Chain Shuffle Repertoires

ScFv antibodies specific to TGF β -1 were identified by both phage and soluble ELISA, and sequenced, as described earlier. Three new TGF β -1-specific scFv antibodies were identified, two with PBL-derived light chains and one with a tonsil-derived light chain. All three had the 1B2 heavy chain sequence (DP49), described earlier. The sequences are summarised below and the complete sequence of each VL domain gene is given in figure 1(b).

CLONE	VL SOURCE	VH GERMLINE	VL ISOTYPE
7-A3	PBL	DP49 (1B2)	VKappa
10-A6	PBL	DP49 (1B2)	VLambda
14-A1	Tonsil	DP49 (1B2)	VLambda

Thus the VH domain 1B2 derived from the PBL library can be combined with VL domains derived from

both PBL and tonsil libraries.

**b. CDR3 'Spiking' of the TGF β -1-Specific ScFv Antibody
1B2**

5

i. Construction of 'spiked' repertoire

An 84 mer mutagenic oligonucleotide primer, 1B2 mutVHCDR3, was first synthesized (see Table 1). This primer was 'spiked' at 10%; i.e. at each nucleotide position there is a 10% probability that a non-parental nucleotide will be incorporated. The 1-B2 heavy chain was amplified by PCR using the primers pUC19reverse and 1B2 mutVHCDR3. Amplification conditions consisted of 30 cycles of 94 °C for 1 min, 55 °C for 1 min and 72 °C for 1min, followed by 10 min at 72 °C. The PCR product was separated through a 1% agarose-TAE gel, the band representing the amplified VH excised, and eluted from the agarose gel using the Geneclean Kit (Bio 101).

The parental 1B2 light chain was amplified by PCR using the primers fdtetseq and RL3 (Table 1). Amplification conditions consisted of 30 cycles of 94 °C for 1 min, 55 °C for 1 min and 72 °C for 1min, followed by 10 min at 72 °C. The PCR product was separated through a 1% agarose-TAE gel, the band representing the amplified VL excised, and eluted from the agarose gel using the Geneclean Kit (Bio 101).

Approximately 50 ng amplified 'spiked' 1-B2 heavy

chain and 50 ng of amplified parental 1B2 light chain were combined and precipitated with sodium acetate and ethanol using 25 µg glycogen as a carrier. The precipitated DNA was pelleted by centrifugation at 5 13,000 rpm in a microfuge, air dried and resuspended in 26 µl H₂O. This was used in an assembly amplification after the addition of reaction buffer to 1X, dNTP's to 200 nM and 5 units Taq polymerase. Amplification conditions consisted of 25 cycles of 94 10 °C for 1 min, 65 °C for 4 min. Five µl of each assembly was used as the template in a 'pull-through' amplification with the primers fdtetseq and pUC19reverse. Amplification conditions consisted of 30 cycles of 94 °C for 1 min, 55 °C for 2 min and 72 °C 15 for 1min, followed by 10 min at 72 °C.

The pull-through amplification product was separated through 1% agarose-TAE and the band representing the pull-through 'spiked' VH -VL excised and eluted using the Geneclean Kit. This was digested 20 with the restriction endonucleases Sfi I and Not I (NEB) and ligated (Amersham ligation system) into the phagemid vector pCantab 6, previously digested with Sfi I and Not I. The ligation product was used to transform electrocompetent TC1 cells, plated out on 25 2YTAG plates and incubated overnight at 30 °C. Approximately 4 x 10⁶ individual clones were generated from this VH CDR3 'spiking' of the 1-B2 VH CDR3.

ii. Selection of 1B2 CDR3 Spike Repertoire

The repertoire was selected for new TGF β -1-specific scFv antibody by one round of panning on 1 μ g/ml TGF β -1 followed by two rounds of selection with biotinylated TGF β -1 at 50 nM using methods as described earlier.

iii. Identification of TGF β -1-Specific ScFv Antibodies from the 1B2 CDR3 Spike Repertoire

ScFv antibodies specific to TGF β -1 were identified by both phage and soluble and phage ELISA, and sequenced, as described earlier. Clone 27C1 was isolated from the spiked repertoire. It is virtually identical to clone 1B2 but with three differences in the heavy chain CDR3. The complete sequence of clone 27C1 is given in figure 1 (c). The 27C1 VH domain was combined with the 10A6 VL domain in the construction of the whole antibody 27C1/10A6 IgG4 (example 2). The properties of this antibody are described in more detail in examples 2 to 6. In addition to 27C1, a large number of other antibodies were isolated with up to 7 of the 14 amino acids differing in CDR3 of the VH domain (Figure 3). These had a similar preference for binding TGF β 1 compared to TGF β 2.

3. Identification and Characterisation of Antibodies to Human TGF β -2 by Selection of Naive and Synthetic Phage Antibody Repertoires

a. Induction of phage antibody libraries

Two different phage antibody repertoires were selected for antibodies to TGF β -2. The VH synthetic
 5 (Nissim et al., 1994) and tonsil (constructed as described earlier) repertoires were each treated as described for TGF β -1 to rescue phagemid particles.

b. Panning of phage antibody library on TGF β -2

10 Phage induced from the two repertoires were each separately panned on TGF β -2 as described earlier for TGF β -1 but using 0.5 μ g/ml TGF β -2 as the coating antigen.

15 c. Identification and Sequencing of TGF β -2-Specific ScFv Antibodies

Individual colonies from the third and fourth round selections were screened by both phage and soluble ELISA as described earlier for TGF β -1 but
 20 using flexible microtitre plates coated with TGF β -2 at 0.2 μ g/ml rather than TGF β -1. Clones were chosen for further analysis if the ELISA signal generated on the TGF β -2-coated plate was at least double that on the uncoated plate. For the specificity ELISA, as
 25 described earlier for TGF β -1, clones were considered to be specific for TGF β -2 if the ELISA signal generated in the TGF β -2 coated well was at least five-fold greater than the signal on either TGF β -1,

BSA or an uncoated well.

d. Sequence and Source of the Initial TGF β -2-Specific ScFv Antibodies

5 Four different TGF β -2 specific antibodies were isolated from the selections using the two libraries described above. Each clone name, its origin and its heavy and light chain germline is given below. The complete sequence of each VH domain gene is given in
10 figure 2 (a) together with the VL domain of Gold-11.

CLONE	LIBRARY SOURCE	VH GERMLINE	VL ISOTYPE
1-G2	Tonsil		
15 1-H6	Tonsil	DP49	
2A-H11	Synthetic VH	DP50	VLambda
2A-A9	Synthetic	DP46	VLambda
Gold-11	Large scFv		VLambda

20 Thus human antibodies binding to human TGF β 2 have been isolated from different sources-, both natural Vgenes of unimmunised humans and synthetic libraries from cloned germline V genes together with synthetic CDRs.

25

4. Light Chain Shuffling of the TGF β -2-Specific ScFv Antibodies 2A-H11 and 2A-A9

a. Construction of Repertoires

The heavy chain of clones 2A-H11 and 2A-A9 were recombined with the complete repertoire of light chains derived from the PBL and large (tonsil-derived) scFv repertoires as described earlier for the TGF β -1-specific scFv antibody 1-B2. Both repertoires generated from the recombination with the PBL light chain repertoire were approximately 1×10^5 , those generated from the recombination with the tonsil light chain repertoire were approximately 1×10^6 .

b. Selection of Light Chain Shuffle Repertoires

The light chain-shuffle repertoires were selected for TGF β -2-specific antibodies using biotinylated TGF β -2, as described earlier for the selection of the TGF β -1 light chain shuffle repertoires. For all of the first and second round selections, a concentration of 100 nM biotinylated TGF β -2 was used. For the third round selection of the PBL-derived light chain shuffle repertoire, biotinylated TGF β -2 was used at concentrations of 100 nM and 1 nM. For the third round selection of the tonsil-derived light chain shuffle repertoire, biotinylated TGF β -2 was used at a concentration of 50 nM.

c. Identification of TGF β -2-Specific ScFv Antibodies from Light Chain Shuffle Repertoires

ScFv antibodies specific to TGF β -2 were

identified by both phage and soluble ELISA, and sequenced, as described earlier. Five new TGF β -2-specific scFv antibodies were identified. The sequences are summarised below and the complete sequence of each clone given in figure 2 (b).

	CLONE	VL	SOURCE	VH GERMLINE	VL ISOTYPE
	6-H1	PBL		DP50. (2A-H11)	VKappa
10	6-A5	PBL		DP50 (2A-H11)	VLambda
	6-B1	PBL		DP50 (2A-H11)	VLambda
	11-E6	PBL		DP46 (2A-A9)	VKappa
	14-F12	Tonsil		DP46 (2A-A9)	VLambda

15 d. Specificity determination by ELISA

Clones identified as binding TGF β -2 rather than uncoated well, as described above, were further analysed for fine specificity. Specificity ELISA's were carried out using scFv either displayed on phage or in solution as described above, except that 5 ml of media in 50 ml Falcon tubes were inoculated with each clone and grown to generate the phage or soluble scFv used in the ELISA. Microtitre plate wells were coated with 50 μ l of either 0.2 μ g/ml TGF β -1, 0.2 μ g/ml TGF β -2, 10 μ g/ml bovine serum albumin (BSA) or PBS (the uncoated well). After preblocking both the phage (or soluble scFv) and the microtitre plates, 50 μ l blocked phage (or soluble scFv) from each clone was

added to a well coated with either TGF β -1, TGF β -2, BSA or an uncoated well. As above, alkaline phosphatase activity was visualised using either the chromagenic substrate pNPP (Sigma) or the Ampak system (Dako). Clones were considered to be specific for TGF β -2 if the ELISA signal generated in the TGF β -2 coated well was at least five-fold greater than the signal on either TGF β -2, BSA or an uncoated well. Cross-reactivity with unrelated antigens was determined more extensively for anti-TGF β 2 antibody in whole antibody format, see example 2. The cross-reactivity of 6B1 IgG4 and 6A5 IgG4 with TGF β 1 and TGF β 3. (obtained from R&D Systems, Abingdon) is also shown to be very low.

e. Specificity determination by BIAcore™

The antibodies were also shown to be specific for TGF β 2 compared to TGF β 1 by relative binding to the BIAcore sensor chips coated with the appropriate antigen. TGF β 1 and TGF β 2 were immobilised by amine coupling to Biosensor CM5 sensor chips (Pharmacia) according to the manufacturers instructions. Single chain Fv fragments (35 μ l; purified by immobilized metal affinity chromatography) were injected over the immobilized antigen at a flow rate of 5 μ l/min. The amount of TGF β bound was assessed as the total increase in resonance units (RUs) over this period. For the single chain Fv fragments 6H1, 6A5 and 14F12,

these fragments gave a total of 686, 480 and 616 RUs respectively for the TGF β 1 coated sensor chip and 77, 71 and 115 RUs respectively for the TGF β 2 coated chip.

5 5. Building higher affinity anti TGF β -1 biological neutralisers

- a. Recombining heavy chains derived from high affinity anti- TGF β 1 scFv with light chains derived from anti-
10 -TGF β 1 and anti-TGF β 2 scFv showing good properties

Antibodies derived by spiking CDR3 of the scFv antibody 1-B2 (section 2b) bind TGF β -1 with high affinity. To improve the chance of obtaining high affinity neutralising antibodies it was decided to
15 chain shuffle VHs derived from high affinity anti-TGF β -1 scFv with VLs derived from scFv clones with promising properties and particularly with those capable of neutralising the activity of TGF β -2 in vitro.

20 Heavy chains were amplified by PCR from the repertoire of CDR3 spiked 1-B2 clones after selection on TGF β -1 (section 2a.ii) using the primers pUC19reverse and PCR-H-Link (Table 1). Amplification conditions consisted of 30 cycles of 94 °C for 1 min,
25 55 °C for 1 min and 72 °C for 1min, followed by 10 min at 72 °C. The PCR product was separated through a 1% agarose-TAE gel, the band representing the amplified VH excised, and eluted from the agarose gel using the

Geneclean Kit (Bio 101).

Light chains were separately amplified by PCR from each of the anti TGF β -1 specific neutralisers (7-A3, 10-A6 and 14-A1; section 2a.iii) and each of the anti TGF β -2 specific neutralisers (6H1, 6A5, 6B1, 11E6 and 14F12; section 4c) using the primers fdte β seq1 and PCR-L-Link (Table 1). The same PCR conditions were used as described for the VH amplification. Each VL PCR product was then separately purified through a 1% agarose-TAE gel as described above. Purified products were finally mixed in approximately equimolar amounts (as estimated from an analytical agarose gel) to provide a VL 'pool'.

Approximately 50 ng amplified heavy chains and 50 ng of amplified pooled light chains were combined and precipitated with sodium acetate and ethanol using 25 μ g glycogen as a carrier. The precipitated DNA was pelleted by centrifugation at 13,000 rpm in a microfuge, air dried and resuspended in 23 μ l H₂O. This was used in an assembly amplification after the addition of reaction buffer, dNTP's to 200 nM and 5 units Taq polymerase. Amplification conditions consisted of 20 cycles of 94 $^{\circ}$ C for 1 min, 55 $^{\circ}$ C for 1 min and 72 $^{\circ}$ C for 2 mins, followed by 10 min at 72 $^{\circ}$ C. 5 μ l of assembly was used as the template in a 50ul 'pull-through' amplification with the primers fdtetseq and pUC19reverse. Amplification conditions consisted of 30 cycles of 94 $^{\circ}$ C for 1 min, 55 $^{\circ}$ C for 1 min and 72

$^{\circ}\text{C}$ for 2mins, followed by 10 min at 72°C .

The pull-through amplification product was separated through 1% agarose-TAE and the band representing the pull-through VH-VL excised and eluted using the Geneclean Kit. This was digested with the restriction endonucleases Sfi I and Not I (NEB) and ligated into the phagemid vector pCantab 6 (McCafferty et al. 1994 supra), previously digested with Sfi I and Not I, using the Amersham ligation system. The ligation product was used to transform electrocompetent TG1 cells, plated out on 2YTAG plates and incubated overnight at 30°C . A repertoire of approximately 3×10^6 individual clones was generated.

b. Selection of chain shuffled repertoire

The chain shuffled repertoire was selected by a single round of panning on TGF β -1 (1 $\mu\text{g}/\text{ml}$), as previously described (section 1b).

c. Identification of TGF β -1 specific scFv antibodies

ScFv antibodies specific to TGF β -1 were identified by phage ELISA and sequenced as described earlier (sections 1d.i and 1e). New TGF β -1 specific scFv antibodies were identified. Two new high affinity clones were isolated -CS32 which consists of 31G9 VH and 7A3 VL and CS39 which consists of 31G9 VH and 6H1 VL.

d. Off-rate determination for single chain Fv fragments binding to TGF β 1 and TGF β 2

The off-rates for binding to TGF β 1 or TGF β 2 of the single chain Fv fragments described in this example were determined as described by Karlsson et al (R. Karlsson et al, J. Immunol. Methods 145, 229-240, 1991). The results obtained are shown in Table 2, together with dissociation constants for those which have been determined. These results indicate that high affinity antibodies have been isolated.

6. Identification and Characterisation of an Antibody which Cross-reacts with both Human TGF β -1 and TGF β -2 but not TGF β -3 by Selection of a Large ScFv Repertoire

a. Panning of the Library and Identification of Binders

The large scFv library (described earlier) was induced, phagemid particles rescued and panned as described earlier with the following modifications. For the first round of panning, 10¹² tu library phage in 0.5 ml PBS were used (rather than the standard 2 ml), for the second round, 3.5 x 10⁹ phage in 0.5 ml PBS were used. The immuno tube was coated with 10 μ g TGF β -2 in 0.5 ml PBS for both the first and second round of selection. Individual colonies from the second selection were screened by ELISA using 0.2 μ g/ml TGF β -1. Clones binding TGF β -1 were further

screened on TGF β -2, TGF β -3, BSA and PBS. Clones were considered to be specific for both TGF β -1 and TGF β -2 if the ELISA signal generated in the TGF β -1 and the TGF β -2 coated wells were both at least five-fold greater than the signal on TGF β -3, BSA and an uncoated well.

c. Identification of a TGF β -1/TGF β -2 Cross-reactive ScFv Antibody

10 A single scFv antibody specific for both TGF β -1 and TGF β -2 was identified by both phage and soluble ELISA, and sequenced, as described earlier. The complete sequence of the VL domain of the antibody gene VT37 is given in figure 4. The dissociation
15 constant of this single chain Fv antibody was estimated by analysis using BIAcore™ to be 4nM for TGF β 1 and 7nM for TGF β 2. Cross-reactivity for TGF β 3 was also determined. Purified VT37scFv at 8.3 μ g/ml was passed over BIAcore™ sensor chips coated with TGF β 1
20 (500RUs coated); TGF β 2 (450RUs coated) or TGF β 3 (5500RUs coated). The relative response for VT37 scFv binding was: TGF β 1 - 391RU bound; TGF β 2 - 261RU bound or TGF β 3 - 24RU bound. Thus this antibody binds strongly to TGF β 1 and TGF β 2 but binding to TGF β 3 is
25 not detectable above background.

Example 2 Construction of Cell Lines Expressing Whole Antibodies

For the construction of cell lines expressing IgG4 antibodies, variable domains were cloned into vectors expressing the human gamma 4 constant region for the VH domains or the human kappa or lambda constant regions for the VL domains.

To construct the whole antibody, 27C1/10A6 IgG4 (specific for TGF β ₁), 27C1 VH DNA was prepared from the clone isolated above, in example 1. The VH gene was amplified by PCR using the oligonucleotides VH3BackSfiEu and VHJH6ForBam (Table 1) with cycles of 1 min at 94°C, 1 min at 55°C, 1.5 min at 72°C. Following digestion with SfiI and BamHI, the VH gene was cloned into the vector vhcassette2 (Figure 5) digested with SfiI and BamHI. Ligated DNA was transformed into E. coli TG1. Ampicillin resistant colonies were obtained and those containing the correct insert identified by DNA sequencing.

Plasmid DNA from these colonies was prepared and the DNA digested with HindIII and BamHI. The HindIII-BamHI restriction fragment was ligated into the human IgG4 heavy chain expression vector pG4D100 (Figure 6), which had been digested with HindIII and BamHI and the DNA transfected into E.coli TG1 by electroporation. The sequence of the VH gene insert was again verified by DNA sequencing.

For the light chain, the VL gene of 10A6, isolated in example 1, was first mutagenized to remove its internal BamHI site using site directed

mutagenesis (Amersham RPN1523) with the oligonucleotide DeltaBamHI (Table 1). The resulting VLDBamHI gene was amplified by PCR using the oligonucleotides VA3/4BackEuApa and HuJλ2-3ForEuBam (Table 1). Following digestion of the amplified insert with ApaLI and BamHI, the VL gene was cloned into the vector vlcassetteCAT1 (Figure 7) digested with ApaLI and BamHI. Ligated DNA was transformed into E.coli TG1. Ampicillin resistant colonies were obtained and those containing the correct insert were identified by DNA sequencing.

Plasmid DNA from these colonies was prepared and the DNA digested with Hind III and BamHI. The HindIII-BamHI restriction fragment containing the leader sequence and the VL domain was ligated into the human lambda light chain expression vector, pLN10 (Figure 8), which had been digested with HindIII and BamHI. Following electroporation, transformants in E.coli were checked by DNA sequencing.

Plasmid DNA was prepared from the pG4D100-27C1 clone and the pLN10-10A6 clone. This DNA was then co-transfected into DUKXB11 Chinese Hamster Ovary (CHO) cells by electroporation (290V; 960μF). The cells were then grown for 2 days in non-selective medium (alpha-MEM plus nucleosides). Cells were then transferred to a selective medium (alpha-MEM plus 1mg/ml G418 without nucleosides) and grown in 96 well plates. Colonies were then transferred to 24 well

plates and samples assayed by sandwich ELISA for assembled human IgG4 antibody and by binding to TGF β 1 in ELISA (as in example 1). For the sandwich ELISA, goat anti-human IgG coated on to the ELISA plate and
5 captured human IgG4 detected using goat antihuman lambda light chain alkaline phosphatase conjugate. High expressing cell lines were then derived by amplification of the inserted genes using selection in the presence of methotrexate (R.J. Kaufman Methods
10 Enzymol. 185 537-566, 1990).

The whole antibody 6H1 IgG4 (specific for TGF β 2) was constructed in a similar way to the above construction of 27C1/10A6 IgG4. The 6H1 VH gene (example 2) was cloned into pG4D100 as for 27C1 above
15 except that PCR amplification was performed with the oligonucleotides VH3BackSfiEu and VHJH1-2FORBam. The 6H1 VL gene (example 2) was subcloned into vlcassetteCAT1 as above except that PCR amplification was performed with the oligonucleotides Vk2BackEuApa
20 and HuJk3FOREuBam. However, since the 6H1 VL is a kappa light chain the HindIII-BamHI fragment was subcloned into the human kappa light chain expression vector pKN100 (Figure 9) which had been digested with HindIII and BamHI. High expressing cell lines were
25 then isolated as described above. Clones expressing antibody were identified from culture plates by sandwich ELISA for assembled human IgG4 antibody (detected using goat anti-human kappa light chain

conjugate and by binding to TGF β 2 in ELISA (as in example 2).

To construct the whole antibodies 6A5 IgG4 and 6B1 IgG4, the same 6H1 VH construct in pG4D100 was used as for 6H1IgG4 since these antibodies all have the same VH gene. The 6B1 and 6A5 genes were each subcloned into vlcassetteCAT1 as above for the 10A6 light chain except that PCR amplification was performed with the nucleotides VA3backEuApa and HuJA2-3ForEuBam. The HindIII-BamHI restriction fragment was then subcloned into pLN10 as above. Clones expressing antibody were identified from culture plates by sandwich ELISA for assembled human IgG4 antibody (detected using goat anti-human kappa light chain conjugate and by binding to TGF β 2 in ELISA (as in example 2).

Properties of whole antibody constructs

20 Purification of whole antibodies

Serum-free supernatant from CHO cells producing the relevant IgG was clarified by centrifugation at 8000 rpm (Beckman JS2-21) prior to purification. The supernatant was applied to a HiTrap Protein A Sepharose prepacked affinity column from Pharmacia, either 1 or 5ml size, with binding capacities of 25 or 120 mg respectively. Each IgG had a dedicated column to avoid any potential carry over of material from one

purification to another. The column was equilibrated to phosphate buffered saline (PBS) with ten column volumes of 1xPBS prior to applying the supernatant. When all the supernatant had been applied to the

5 column at a flow rate of 2-4 ml/minute, again, depending on the column size, the column was washed with ten column volumes of 1xPBS to remove any non-specifically bound material. Elution of the bound protein was achieved using 0.1M sodium acetate,

10 adjusted to pH 3.3 with glacial acetic acid. The eluted material was collected in 8 fractions of 1.5 ml volume, and the amount of protein determined by measuring the absorbance at 280nm, and multiplying this value by 0.7 to get a value in mg/ml. This was

15 then neutralised with 0.5ml of 1M Tris.HCl pH 9.0 per 1.5ml fraction, and the protein-containing fractions pooled and dialysed against 1x PBS to buffer exchange the IgG. The column was returned to neutral pH by running ten column volumes of 1xPBS through, and was

20 stored in 20% ethanol as a preservative until required again.

A sample was then run on 10-15% SDS-PAGE (Phast system, Pharmacia) and silver stained. this allowed an assessment of the purity of the IgG preparation.

25 This was usually found to be about 80-90%, with only a couple of other bands prominent on the stained gel.

Binding specificity by ELISA

The IgG4 antibodies 6B1 and 6A5 were shown to bind TGF β 2 with very low cross-reactivity to TGF β 1 and TGF β 3 and no detectable cross-reactivity with a range of non-specific antigens: interleukin-1; human lymphotoxin (TNF β); human insulin; human serum albumin; single stranded DNA; oxazolone-bovine serum albumin; keyhole limpet haemocyanin; chicken egg white trypsin inhibitor; chymotrypsinogen; cytochrome c; glyceraldehyde phosphate dehydrogenase; ovalbumin; hen egg lysozyme; bovine serum albumin and tumour necrosis factor α - (TNF α) (Figure 13(a) and (b)). Likewise the antibodies 6B1, 6A5 and 6H1 IgG4 bound strongly to TGF β 2 coated on a BIAcore™ sensor chip but not significantly to TGF β 1 or TGF β 3 coated chips.

15

Binding properties of whole antibodies by BIAcore™

The affinity constants of the above antibodies were determined by BIAcore™, using the method of Karlsson et al. J. Immunol. Methods 145, 299-240, 1991 (supra) and found to be approximately 5nM for 27C1/10A6 IgG4 for TGF β 1 and 2nM for 6H1 IgG4 for TGF β 2. The antibody 27C1/10A6 IgG4 also shows some cross-reactivity with TGF β 2 coated onto Biosensor chips but the dissociation constant is approximately 10 fold or more higher for TGF β 2 compared to TGF β 1. There was no significant cross-reactivity with lysozyme coated onto a BIAcore™ sensor chip.

25

Neutralisation and inhibition of radioreceptor

binding by IgG4 antibodies to TGF β 1 and TGF β 2 is described in examples 3 and 4.

5 Example 3 Neutralisation by Antibodies of the
 Inhibitory Effect of TGF β 1 and TGF β 2 on Cell
 Proliferation

 The neutralising activity of the antibodies described in examples 1 and 2 were tested in a modification of a bioassay for TGF β as described by
10 Randall et al (1993) J. Immunol Methods 164, 61-67. This assay is based on the ability of TGF β ₁ and TGF β ₂ to inhibit the interleukin-5 induced proliferation of the erythroleukaemia cell line, TF1 and being able to reverse this inhibition with specific TGF β
15 antibodies.

Method

Cells and maintenance

20 The human erythroleukaemia cell line TF1 was grown in RPMI 1640 medium supplemented with 5% foetal calf serum, penicillin/streptomycin and 2ng/ml rhGM-CSF in a humidified incubator containing 5% CO₂ at 37°C. Cultures were passaged when they reached a
25 density of 2 X 10⁵/ml and diluted to a density of 5 x 10⁵/ml.

Cytokines and Antibodies

rhGM-CSF and rhIL-5 were obtained from R&D systems, rhTGF β_2 was obtained AMS Biotechnology. Rabbit anti TGF β_2 antibody was from R&D Systems and Mouse anti-TGF $\beta_{1,2,3}$ was from Genzyme. Other
5 antibodies against TGF β_2 were as described in examples 1&2.

Titration of Inhibition of Proliferation by TGF β_2 .

Doubling dilutions of TGF β_2 (800pM - 25pM) for
10 the construction of a dose response curve were prepared on a sterile microtitre plate in 100 μ l of RPMI 1640 medium containing 5% foetal calf serum and antibiotics. All dilutions were performed at least in quadruplicate. Additional wells containing 100 μ l of
15 the above medium. for reagent and cells only controls were also included.

TF1 cells were washed twice in serum free RPMI 1640 medium and resuspended in RPMI 1640 medium supplemented with 5% foetal calf serum, 100U/ml
20 penicillin and 100 μ g/ml streptomycin and 4ng/ml rhIL-5 at a density of 2.5×10^5 /ml. Aliquots of 100 μ l were added to the previously prepared dilution series and the plate incubated for 48hr. in a humidified incubator containing 5% CO₂ at 37°C.

25 Cell proliferation was measured colourimetrically by addition of 40 μ l CellTiter96 substrate (Promega), returning the plate to the incubator for a further 4hr and finally determining the absorbance at 490nm. The

percentage inhibition for each concentration of TGF β_2 as compared to cell only wells was then calculated.

Assay for Neutralisation of TGF β_2 Inhibitory Activity
5 by Anti-TGF β_2 Antibodies

Neutralisation of TGF β_2 was determined by making doubling dilutions in of each purified antibody in 100 μ l of medium as above. TGF β_2 was added to each antibody dilution to give a final concentration
10 equivalent to that which gave 50% inhibition in the titration described above. Each dilution was prepared in quadruplicate. Additional wells were prepared for antibody only, cells only and reagent controls. Cell preparation and determination of cell proliferation
15 was performed as described above.

Results

TGF β_2 was shown to inhibit the proliferation of TF1 cells by 50% at a concentration of 50pM. This
20 concentration was used for all neutralisation experiments.

These assays showed that TGF β_2 activity was neutralised in a dose dependant manner for both scFv fragments (figure 10) and for whole IgG4 antibodies
25 (figure 11). The concentration of antibody which gave 50% inhibition was determined from the graphs and is shown in table 4.

Example 4 Inhibition by antibodies of TGF β binding to receptors measured in a radioreceptor assay

Single chain Fv fragments and whole IgG4 antibodies from different clones were expressed and
5 purified and their ability to inhibit binding of TGF β to receptors measured in a radioreceptor assay.

PURIFICATION OF scFv

ScFvs containing a poly histidine tail are
10 purified by immobilised metal affinity chromatography. The bacterial clone containing the appropriate plasmid is inoculated into 50 ml 2TY medium containing 2% glucose and 100 μ g/ml ampicillin (2TYAG) and grown overnight at 30°C. The next day the culture is added
15 to 500 ml prewarmed 2TYAG and grown at 30°C for 1 h. The cells are collected by centrifugation and added to 500 ml 2TY containing ampicillin and 1 mM IPTG and grown at 30°C for 4 h. The cells are then collected by centrifugation and are resuspended in 30 ml
20 ice-cold 50 mM Tris HCl pH 8.0, 20% (w/v) sucrose, 1 mM EDTA. After 15 min end-to-end mixing at 4°C the mixture is centrifuged at 12 k rpm for 15 min at 4°C. The supernatant is removed and to it added ~ 1ml NTA-agarose (Qiagen 30210) and mixed at 4°C for 30
25 min. The agarose beads are washed extensively with 50 mM sodium phosphate, 300 mM NaCl and loaded into a small column. After further washing with 50 mM sodium phosphate, 300 mM NaCl, 10 mM imidazole pH 7.4 scFv is

eluted with 50 mM sodium phosphate, 300 mM NaCl, 250 mM imidazole pH 7.4. 0.5 ml fractions are collected and the protein containing fractions identified by measuring the $A_{280\text{nm}}$. Pooled fractions are

5 concentrated and scFv further purified by gel filtration in PBS on a Superdex 75 column (Pharmacia).

PURIFICATION OF WHOLE ANTIBODIES

Whole IgG4 antibodies were purified as described

10 in example 2.

RADIORECEPTOR ASSAY FOR TGF- β

Neutralisation of TGF- β activity is measured by the ability of the scFvs and IgGs to inhibit the

15 binding of $^{125}\text{-I}$ labelled TGF- β to its receptors on A549 human lung carcinoma cells.

A549 cells (ATCC CCL 185) are grown in high glucose Dulbecco's modified Eagle's medium (Sigma D-6546) supplemented with 10% foetal calf serum (PAA),

20 2 mM glutamine (Sigma G-7513), penicillin/streptomycin (Sigma P-0781), MEM non-essential amino acids (Sigma M-7145).

Cells are seeded at $1-2 \times 10^5$ cells / ml / well into the wells of 24-well cluster plates and grown

25 for 24 h in serum-free DMEM. Cell monolayers are washed twice with serum-free DMEM and 0.5 ml binding medium (DMEM/Hams F12 (Sigma D-6421) containing 0.1% (v/v) BSA added to each well.

Aliquots of ^{125}I -TGF- β_1 or - β_2 (70-90 TBq/mmol; Amersham International) at 20 pM are preincubated with antibody in binding medium at room temperature for 1 h. Duplicate samples of 0.5 ml of TGF- β /antibody mixtures are then added to the cell monolayers and are incubated at 37°C for 1-2 h. Control wells contain TGF- β only. Unbound TGF- β is removed by washing 4 times with Hank's balanced salt solution containing 0.1% BSA. Cells are solubilised in 0.8 ml 25 mM Tris HCl pH 7.5, 10 % glycerol, 1 % Triton X-100 at room temperature for 20 min. The contents of each well are removed and ^{125}I measured in a gamma counter. The potency of each scFv or IgG is measured by the concentration of antibody combining sites necessary to inhibit binding of TGF- β by 50% (IC₅₀; Table 5). Thus the IC₅₀ values are below 10nM and in some cases below 1nM indicating very potent antibodies.

Example 5 Prevention of Scar Formation by Antibodies Against TGF β_1 and TGF β_2 in the Injured Central Nervous System of the Rat

Logan et al (1994) Eur. J Neuroscience 6, 355-363 showed in a rat model of CNS injury, the ameliorating effect of a neutralising turkey antiserum directed against TGF β_1 on the deposition of fibrous scar tissue and the formation of a limiting glial membrane that borders the lesion. A study was set up to investigate the effects of neutralising engineered

human antibodies directed against both TGF β_1 and TGF β_2 in the same rat model. The derivation of the antibodies used in this study is described in examples 1 and 2.

5

Method

Animals and surgery

Groups of five female Sprague-Dawley rats (250g) were anaesthetised with an i.p. injection. The anaesthetised rats had a stereotactically defined lesion made into the right occipital cortex (Logan et al 1992 Brain Res. 587, P216-227) and the lateral ventricle was surgically cannulated and exteriorised at the same time (Logan et al 1994 supra).

Neutralisation of TGF β

Animals were intraventricularly injected daily with 5ul of purified anti TGF β antibodies (Table 3) diluted in a vehicle of artificial cerebrospinal fluid as described by Logan et al 1994 supra. Fourteen days post lesion all animals were perfusion fixed and 7mm polyester wax sections were processed for histochemical evaluation of the lesion site by immunofluorescent staining.

Fluorescent immunohistochemistry and image analysis

Morphological changes within the wound site were

followed by immunofluorescent staining with antibodies to fibronectin and laminin detected with anti-species FITC conjugates (Logan et al 1994 supra). These changes were semi-quantitatively assessed by image analysis using a Leitz confocal microscope linked to a Biorad MRC500 laser scanning system. Readings were taken at standard positions mid-way along the lesion.

Results

Effects of antibodies to TGF β at the site of CNS injury

Quantitation of the specific relative fluorescence for each of the antibodies is shown in figure 12 a and b. Laminin is a measure of the formation of the glial limitans externa along the boundaries of the wound and together with fibronectin forms a matrix of fibrous tissue within the centre of the wound. Quantitation by image analysis of these two proteins allows the degree of scarring at the wound site to be determined.

Compared with the saline control (fig.12 a,b), There is a considerable decrease in fibronectin and laminin immuno-localisation in the wound in the anti-TGF β antibody treated brains. Thus this indicates that these engineered human antibodies directed against epitopes on TGF β_1 & TGF β_2 ameliorate the effects of injury to the CNS both separately and

together. by preventing the deposition of the cellular matrix proteins fibronectin and laminin within the wound site. Previously Logan et al (1994 supra) had shown the effectiveness of a polyclonal
5 turkey anti-sera directed against TGF β_1 . This is the first report of any antibodies directed against TGF β_2 having been shown to be effective in this model.

**Example 6 Suppression of experimental
10 glomerulonephritis using human antibodies against human TGF β**

The ability of human antibodies against human TGF β to neutralise TGF β activity, and thus prove beneficial in the treatment of fibrotic disease, was
15 tested in an animal model of the kidney disease, glomerulonephritis.

Antibodies directed against TGF β_1 have been shown to be effective in the suppression of experimental glomerulonephritis (W.A. Border et al Nature 346
20 371-374, 1990) and other fibrotic diseases (W.A. Border & N.A. Noble New Engl. J. Med. 331 1286-1292, 1994). In this example, it is shown that antibodies directed against either TGF β_1 or TGF β_2 are effective in the treatment of glomerulonephritis. Induction of
25 glomerulonephritis in rats with a single injection of anti-thymocyte serum was followed by treatment with an injection of either antibody directed against TGF β_1 or of saline.

31G9 and 6A5 scFv (example 1) were expressed using a T7 polymerase controlled vector system (J.H. Christensen et al FEBS Lett. 281 181-184, 1991). Active scFv protein was prepared from inclusion bodies using the methodology described in WO94/18227 (H.C. Thøgersen et al). The scFv preparations were homogeneous as determined by SDS-PAGE and by gel filtration chromatography on Superose 12.

Five groups of rats were used-

- 10 Group A: Normal controls, no anti-thymocyte serum treatment
- Group B: Disease control (saline treatment)
- Group C: Treatment daily with 25µg 31G9 single chain Fv (anti-TGFβ₁)
- 15 Group D: Treatment daily with 25µg 6A5 single chain Fv (anti-TGFβ₂)
- Group E: Treatment daily with 25µg 31G9 and 8µg 6A5 single chain Fv

- 20 Groups B to E each received a dose of 0.25ml sheep anti-thymocyte serum (ATS; Border et al, 1990 supra). One hour after ATS injection, each group received 200µl PBS (group B) or the appropriate antibody (200µl in PBS). On days 1 to 5, these doses
- 25 were repeated for groups B to E. On day 6, all rats were sacrificed.

Urinary protein was measured (a measure of glomerular injury: J.M. Ginsberg et al New Engl. J.

Med. 309 1543-1550, 1983) for 24h on days 5 to 6 and was found to be significantly lower for the rats treated with 6A5 scFv than for the disease control (see Figure 14). The extent of glomerular injury was
5 determined by examination of glomeruli stained with periodic acid-Schiff's base (30 glomeruli for each rat). These glomeruli are scored for the extent of glomerular matrix accumulation (30 glomeruli for each rat) on histological examination of stained sections
10 (Border et al, 1990 supra; W.A. Border et al Nature 360 361-364, 1992). Scoring was performed by two independent scientists for each rat. There was a significantly lower increase in extracellular matrix deposition for the 6A5 scFv treated rat compared to
15 the disease control (Figure 15). There was also a somewhat lower increase for 31G9 scFv but this difference in deposition was not statistically significant.

Hence the human antibody against human $TGF\beta_2$ is
20 effective in suppression of experimental glomerulonephritis.

Example 7 Neutralisation by antibodies directed
against $TGF\beta_2$ of the inhibitory effect of $TGF\beta$
25 isoforms on cell proliferation

The neutralising activity of 6B1 IgG4, 6H1 IgG4 (purified as in example 2) and a mouse monoclonal antibody (Genzyme; J.R. Dasch et al., supra) was

measured for each of the TGF β isoforms, TGF β 1, TGF β 2 and TGF β 3 in the TF1 cell proliferation assay described in Example 3. The concentration of TGF β isoform was 100pM in each assay.

- 5 As shown in Figure 16, 6B1 IgG4 strongly neutralises TGF β 2 with an IC₅₀ of approximately 2nM (Table 6). This compares to 10nM for the mouse monoclonal from Genzyme and 12nM for 6H1 IgG4. Neither 6B1 IgG4 nor 6H1 IgG4 significantly neutralise
- 10 TGF β 1 (Fig. 17). However, there is significant neutralisation of TGF β 3 by both 6B1 (IC₅₀ ca. 11nM) and 6H1 IgG4 ca. 20nM; Fig. 18). This is considerably less than the neutralisation potency of the Genzyme monoclonal (IC₅₀ ca. 0.1nM).
- 15 Both 6B1 IgG4 and 6H1 IgG4 are stronger neutralisers of TGF β 2 activity than of TGF β 3 activity. The neutralisation of TGF β 3 activity is greater than would be predicted from the relative binding of these two isoforms by the antibodies
- 20 (example 2) and the relative binding in a radioreceptor assay (example 8).

Example 8 Inhibition by antibodies directed against
TGF β 2 of binding of other TGF β isoforms to receptors
25 measured in a radioreceptor assay

The ability of 6B1 IgG4 to inhibit binding of TGF β isoforms to receptors was measured in a radioreceptor assay as described in example 4.

6B1 IgG4 inhibited binding of ^{125}I -TGF β 2 with an IC_{50} of 0.05nM. There was no significant inhibition of binding of ^{125}I -TGF β 1 whereas for ^{125}I -TGF β 3 6B1 IgG4 inhibited binding with an IC_{50} of approximately 4nM (Table 6). This indicates the potency of 6B1 IgG4 in this assay and its selectivity for the neutralisation of TGF β 2 activity. Cross-reactivity with TGF β 3 in this assay is less than 2%.

Thus 6B1 IgG4 preferentially inhibits the binding of TGF β 2 to its receptors compared with binding of TGF β 3.

Table 1: Oligonucleotide primers used in the identification and characterisation of TGF- β 1 antibodies.

Primer	Nucleotide sequence 5' to 3'
1B2 mu-VHCDR3	5' CGT GGT CCC TTT GCC CCA GAC GTC CAC ACC ACT AGA ATC GTA GCC ACT ATA TTC CCC AGT TCG CGC ACA GTA ATA CAC AGC.CGT
pUC19reverse	5' AGC GGA TAA CAA TTT CAC ACA GG 3'
fdtet seq	5' GTC GTC TTT CCA GAC GTT AGT 3'
PCR-H-Link	5' ACC GCC AGA GCC ACC TCC GCC 3'
PCR-L-Link	5' GGC GGA GGT GGC TCT GGC GGT 3'
myc seq 10	5' CTC TTC TGA GAT GAG TTT TTG 3'
HuJH4-5For	5' TGA GGA GAC GGT GAC CAG GGT TCC 3'
RL1	5' G(C/A)A CCC TGG TCA CCG TCT CCT CA GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC GGT GGC GGA TCG 3'
RL2	5' GGA CAA TGG TCA CCG TCT CTT CA GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC GGT GGC GGA TCG 3'
RL3	5' GGA CCA CGG TCA CCG TCT CCT CA GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC GGT GGC GGA TCG 3'
VH1b/7a back Sfi	5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG (AG)TG CAG CTG GTG CA(AG) TCT GG-3'
VH1c back Sfi	5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC (GC)AG GTC CAG CTG GT(AG) CAG TCT GG-3'

VH2b back Sfi
 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG (AG)TC ACC TTG AAG GAG TCT GG-3'

 VH 3b back Sfi
 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC (GC)AG GTG CAG CTG GTG GAG TCT GG-3'

 VH3c back Sfi
 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAG GTG CAG (AT)C(TC) GG-3'

 VH4b back Sfi
 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG GTG CAG CTA CAG CAG TCG GG-3'

 VH4c back Sfi
 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG (GC)TG CAG CTG CAG GAG TC(GC) GG-3'

 VH5b back Sfi
 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GA(AG) GTG CAG CTG GTG CAG TCT GG-3'

 VH 5a back Sfi
 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG GTA CAG CAG TCA GG-3'

 VH3ACKSfiEu 5' - AGC TCG GTC CTC GCA ACT GCG GCC CCT GGG GCC CAC AGC GAG GTG CAG CTG GTG
 GAG TCT GG - 3'

 VEHJH6FORBam 5' -CGA GTC ATT CTG CAC TTG GAT CCA CTC ACC TGA GGA GAC GGT GAC CGT GGT CCC - 3'

 Del-aBamHI 5' -GA GAA TCG GTC TCG GAT TCC TGA GGG CCG G-3'

 VA3/4BackEuApa 5' - AGC TCG GTC CTC GCA ACT GGT GTG CAC TCC CAC GTT ATA CTG ACT CAG GAC CC -3'

 HuJA2-3ForEuBam 5' -G GTC CTC GCA ACT GCG GAT CCA CTC ACC TAG GAC GGT CAG CTT GGT CCC- 3'

 VEHJH1-2FORBam 5' -CGA GTC ATT CTG CAC TTG GAT CCA CTC ACC TGA GGA GAC GGT GAC CAG GGT GCC - 3'

VK2BackEuApa 5'- AGC TCG GTC CTC GCA ACT GGT GTG CAC TCC GAT GTT GTG ATG ACT CAG TCT CC-3'

HuJKForEuBam 5'-G GTC CTC GCA ACT GCG GAT CCA CTC ACG TTT GAT ATC CAC TTT GGT CCC -3'

V13BackEuApa 5'- AGC TCG GTC CTC GCA ACT GGT GTG CAC TCC TCG TCT GAG CTG ACT CAG GAC CC -3'

Table 2 Properties of single chain Fv fragments for binding to TGFbeta1 or TGFbeta2 determined using BIAcore

<i>Antibody</i>	<i>k_{off} (s⁻¹)</i>	<i>K_d(nM)</i>
<u>TGFbeta1</u>		
31G9	9.0×10^{-4}	12
CS32	1.2×10^{-3}	
CS39	1.7×10^{-3}	
<u>TGFbeta2</u>		
6A5	1.4×10^{-4}	0.7
6B1	6.0×10^{-4}	
6H1	1.1×10^{-3}	
14F12	2.1×10^{-3}	

Table 3 Daily dose levels for individual animals in each group

Group	Clone	Antibody format	Antigen	Dose
1	Saline Control	-	-	-
2	31G9	scFv	TGF β_1	20ng
3	6A5	scFv	TGF β_2	20ng
4	27C1/10A6	IgG4	TGF β_1	692ng
5	6H1	IgG4	TGF β_2	1.76 μ g
6	31G9 +6A5	scFv's	TGF β_1 TGF β_2	20ng "
7	27C1/10A6 + 6H1	IgG4's	TGF β_1 TGF β_2	692ng 1.76 μ g

Table 4 I.C.₅₀ values for antibodies in TF1 assay

Antibody	scFv (nM)	IgG4 (nM)
6H1	1.5	100
6B1	15	11
6A5	8	150
14F12	90	nd

nd = not determined

Table 5 IC₅₀ values for antibodies measured using a radioreceptor assay.

Anti-TGF- β 1 antibody	IC ₅₀ , nM
------------------------------	-----------------------

7A3 scFv	>100
----------	------

31G9 scFv	30
-----------	----

CS32 scFv	4.5
-----------	-----

CS39 scFv	~60
-----------	-----

27C1/10A6 IgG	9
---------------	---

VT37 scFv	~100
-----------	------

Anti-TGF- β 2 antibody	IC ₅₀ , nM
------------------------------	-----------------------

6A5 scFv	1.5
----------	-----

6A5 IgG	~6
---------	----

6B1 scFv	0.3
----------	-----

6B1 IgG	0.6
---------	-----

6H1 scFv	0.22
----------	------

6H1 IgG	~10
---------	-----

11E6 IgG	1.6
----------	-----

14F12 scFv	3
------------	---

VT37 scFv	2
-----------	---

Table 6 Potency of neutralisation of TGFbeta isoforms

<i>TF1 cell proliferation assay IC₅₀ (nM IgG)</i>		
	<u>6B1 IgG4</u>	<u>Genzyme</u>
TGFbeta1	>100	1.5
TGFbeta2	2	10
TGFbeta3	11	0.1
<i>A549 cell radioreceptor assay IC₅₀ (nM IgG)</i>		
	<u>6B1 IgG4</u>	<u>Genzyme</u>
TGFbeta1	>400	0.55
TGFbeta2	0.05	0.5
TGFbeta3	4	0.03

(a) Antibodies to TGF β 1 isolated directly from repertoires

Sequence Range: 1 to 369

PAGE 249/352 * RCVD AT 9/13/2007 6:05:35 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/22 * DWS:2730844 * CSID:13128932192 * DURATION (mm:ss):82:22

250 * * * * * 260 * * * * * 270 * * * * * 280 * * * * *
 CTG CAA ATG AAC AGC CTG AGA GCT AGA GAG GAC ACG GCT GTG TAT TAC TGT
 L Q M N S L R A E D T A V Y Y C>
 a a a a TRANSLATION OF 7A3 VH.SEQ [A] a a a a a a
 290 * * * * * 300 * * * * * 310 * * * * * 320 * * * * * 330 * * * * *
 GCG AAA ACT GGG GAA TAT AGT GGC TAC GAT TCT AGT GGT GTG GAC GTC
 A K T G E Y S G Y D S S G V D V>
 a a a a TRANSLATION OF 7A3 VH.SEQ [A] a a a a a a
 340 * * * * * 350 * * * * * 360 * * * * *
 TGG GGC AAA GGG ACC ACG GTC ACC GTC TCC TCA
 W G K G T T V T V S S>
 a a TRANSLATION OF 7A3 VH.SEQ [A] a a a a a a

(ii) 1A-E5 VH

Sequence Range: 1 to 345

10 * * * * * 20 * * * * * 30 * * * * * 40 * * * * *
 GAG GTG CAG CTG GTG GAG TCT GGT GGA GGC TTA GTT CAG CCT GGG GGG
 E V Q L V E S G G G L V Q P G G>
 a a a a TRANSLATION OF 1AE-5 VH [A] a a a a a a
 50 * * * * * 60 * * * * * 70 * * * * * 80 * * * * * 90 * * * * *
 TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT AGC TAC
 S L R L S C A A S G F T F S S Y>
 a a a a TRANSLATION OF 1AE-5 VH [A] a a a a a a
 100 * * * * * 110 * * * * * 120 * * * * * 130 * * * * * 140 * * * * *

TGG ATG CAC TGG GTC CGC CAA GCT CCA GGG AAG GGG CTG GTG TGG GTC
W N H W V R Q A P G K G L V W V>
_a_a_a_a_TRANSLATION OF 1AE-5 VH [A]_a_a_a_a_a_>

150 * * * * * 170 * * * * * 180 * * * * * 190 *
* * * * *
TCA CGT ATT AAT AGT GAT GGT AGT AGC ACA AGC TAC GCG GAC TCC GTG
S R I N S D G S S T S Y A D S V>
_a_a_a_a_a_TRANSLATION OF 1AE-5 VH [A]_a_a_a_a_a_>

200 * * * * * 210 * * * * * 220 * * * * * 230 * * * * * 240 *
* * * * *
AAG GGC CGA TTC ACC ATC TCC AGA GAC AAC GCC AAG AAC ACG CTG TAT
K G R F T I S R D N A K N T L Y>
_a_a_a_a_a_TRANSLATION OF 1AE-5 VH [A]_a_a_a_a_a_>

250 * * * * * 260 * * * * * 270 * * * * * 280 * * * * *
* * * * *
CTG CAA ATG AAC AGT CTG AGA GCC GAG GAC ACG GCC GTG TAT TAC TGT
L Q M N S L R A E D T A V Y Y C>
_a_a_a_a_a_TRANSLATION OF 1AE-5 VH [A]_a_a_a_a_a_>

290 * * * * * 300 * * * * * 310 * * * * * 320 * * * * * 330 *
* * * * *
GCA AGG GAG AAT AGT TAT GTG CCT TGG GGG CAG GCC ACC CTG GTC ACC
A R E N S Y V P W G Q G T L V T>
_a_a_a_a_a_TRANSLATION OF 1AE-5 VH [A]_a_a_a_a_a_>

340 * *
* *
GTC TCC TCA
V S S>
_a_a_a_a_a_>

(iii) 1A-H6 VH

Sequence Range: 1 to 354

10 20 30 40
* * * *
CAG GTG CAA CTG CAG GAG TCG GCG GGA GGC GTG CTC CAG CCT GGG GGG
Q V Q L Q E S G G G V V Q P G G>
_a_a_a_a_translation of 1AH-6 VH [A]_a_a_a_a_a>
50 60 70 80 90
* * * *
TCC CTG AGA CTC TCC TGT GCA GCG TCT GGA TTC ACC TTC AGT GGC TAT
S L R L S C A A S G F T F S G Y>
_a_a_a_a_translation of 1AH-6 VH [A]_a_a_a_a_a>
100 110 120 130 140
* * * *
GGC ATG CAC TCG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG GTG
G M H W V R Q A P G K G L E W V>
_a_a_a_a_translation of 1AH-6 VH [A]_a_a_a_a_a>
150 160 170 180 190
* * * *
GCA TCT GTA CCG AAC GAT GGA AGT AAT ACA TAC TAC ACA GAC TCC GTG
A S V R N D G S N T Y Y T D S V>
_a_a_a_a_translation of 1AH-6 VH [A]_a_a_a_a_a>
200 210 220 230 240
* * * *
AAG GGC CGA TTC ACC ATC CCC AGA GAC AAC ACC AAG AAC ACG CTG TAT
K G R F T I P R D N T K N T L Y>
_a_a_a_a_translation of 1AH-6 VH [A]_a_a_a_a_a>
250 260 270 280
* * * *
CTG CAA ATG AAC ACC CTG AGA GCC GAG GAC ACG GCC GTA TAT TAC TGT
L Q M N S L R A E D T A V Y Y C>

150 * 160 170 180 190
 * * * * *
 GCA GTT ATA TCA TAT GAT GGA AGT ATT AAA TAC TAT GCA GAC TCC GTG
 A V I S Y D G S I K Y Y A D S V>
 _a_a_a_ TRANSLATION OF 31G9 VH.SEQ [A]_a_a_a_a_>

200 210 220 230 240
 * * * * *
 AAG GGC CGA TTC ACC ATC TCC AGA GAC AAT TCC AAG AAC ACG CTG TAT
 K G R F T I S R D N S K N T L Y>
 _a_a_a_ TRANSLATION OF 31G9 VH.SEQ [A]_a_a_a_a_>

250 260 270 280
 * * * * *
 CTG CAA ATG AAC AGC CTG AGA GCT GAG GAC ACG GCT GTG TAT TAC TGT
 L Q M N S L R A E D T A V Y Y C>
 _a_a_a_ TRANSLATION OF 31G9 VH.SEQ [A]_a_a_a_a_>

290 300 310 320 330
 * * * * *
 GCG CGA ACT GGT GAA TAT AGT GGC TAC GAT ACG AGT GGT GTG GAG CTC
 A R T G E Y S G Y D T S G V E L>
 _a_a_a_ TRANSLATION OF 31G9 VH.SEQ [A]_a_a_a_a_>

340 350 360
 * * * * *
 TGG GGG CAA GGG ACC ACG GTC ACC GTC TCC TCC TCA
 W G Q G T T V T V S S>
 _a_a_a_ TRANSLATION OF 31G9 VH.SEQ [A]

(v) 31G9 VL

10 20 30 40
 * * * * *
 GAC ATC GTG ATG ACC CAG TCT CCT TCC ACC CTG TCT GCA TCT GTA GGA

[illegible]

Figure 1 (b) Light chains of antibodies to TGFbeta1 isolated by chain shuffling

7A3 VL

Sequence Range: 1 to 342

*
GAG ATC GTG ATG ACC CAG TCT CCA GAC TTC CTG GCT GTG TCT CTG GGC
D I V M T Q S P D S L A V S L G>
TRANSLATION OF 7A3 VL-SEQ [A] - a a a a a a a a

50	60	70	80	90
* GAG	* ACC	* AAC	* TCC	* AGC
* AGG	* ATC	* TGC	* AGC	* CTT
* R A T	* I N C	* X S S	* Q S L	* T T A
a a a	a a a	a a a	a a a	a a a
TRANSLATION OF 7A3 VL-SEQ [A]				
E				S>

[illegible]

* * *
CCT AAG CTC ATT AAC TGG GCA TCT ACC CGG GAA TTC GGG GTC
P P K L L I N W A S T R E S G V>
a a a a TRANSLATION OF 7A3 VL SEQ [A] a a a a a a

	200	210	220	230	240
* *	*	*	*	*	*
CCCT	GAC	TTC	AGT	GGC	AGC
CGA	TTC	AGT	GGC	AGC	GGG
ACA	GAT	TTC	ACT	CTC	ACC
P	D	R	F	S	G
S	G	S	G	S	G
T	D	F	T	L	T
T	T	T	T	T	T


```

*      *      *      *      *      *      *      *      *      *
AGT TGG TAC CAG CAG AAG CCA GGA CAG GCC CCT GTA CTT GTC ATC TAT
S   W   Y   Q   Q   K   P   G   Q   A   P   V   L   V   I   Y>
a   a   a   a   a   a   a   a   a   a   a   a   a   a   a>
TRANSLATION OF 10A6 VL.SEQ [A]_a_a_a_a_a_a_a>

150      *      *      *      *      *      *      *      *      *
GGT GAA AAC AGC CGG CCC TCC GGG ATC CCA GAC CGA TTC TCT GGC TCC
G   E   N   S   R   P   S   G   I   P   D   R   F   S   G   S>
a   a   a   a   a   a   a   a   a   a   a   a   a   a   a>
TRANSLATION OF 10A6 VL.SEQ [A]_a_a_a_a_a_a_a>

200      *      *      *      *      *      *      *      *      *
AGC TCA GGA AAC ACA GCT TCC TCC ACC ATC ACT GGG GCT CAG GCG GAA
S   S   G   N   T   A   S   L   T   I   T   G   A   Q   A   E>
a   a   a   a   a   a   a   a   a   a   a   a   a   a   a>
TRANSLATION OF 10A6 VL.SEQ [A]_a_a_a_a_a_a_a>

250      *      *      *      *      *      *      *      *      *
GAT GAA GCT GAC TAT TAC TGT AAC TCC CGG GAC AGC AGT GGT ACC CAT
D   E   A   D   Y   Y   C   N   S   R   D   S   S   G   T   H>
a   a   a   a   a   a   a   a   a   a   a   a   a   a   a>
TRANSLATION OF 10A6 VL.SEQ [A]_a_a_a_a_a_a_a>

300      *      *      *      *      *      *      *      *      *
CTA GAA GTG TTC GGC GGA GGG ACC AAG CTG ACC GTC CTA GGT
L   E   V   F   G   G   G   T   K   L   T   V   L   G
a   a   a   a   a   a   a   a   a   a   a   a   a   a   a>
TRANSLATION OF 10A6 VL.SEQ [A]_a_a_a_a_a_a_a>

```

Figure 1 (c) Antibodies to TGF β 1 isolated from CDR3 spiking experiment

(i) 27C1 V:H

Sequence Range: 1 to 369

Year	1990	2000	2010	2020
Population (millions)	1.2	1.5	1.8	2.1
GDP (trillion USD)	0.5	1.2	2.5	4.0
Life expectancy (years)	75	78	80	82
Urbanization (%)	45	55	65	75
Renewable energy (%)	10	15	20	25
Carbon emissions (Gt CO2)	0.5	1.0	1.5	2.0
Healthcare spending (% GDP)	5	7	9	11
Education spending (% GDP)	3	4	5	6
Research & Development (% GDP)	2	3	4	5
Unemployment (%)	10	12	15	18
Income inequality (Gini Index)	0.45	0.48	0.50	0.52
Government debt (% GDP)	20	25	30	35
Immigration (millions)	0.1	0.2	0.3	0.4
Trade share (% GDP)	15	20	25	30
Internet usage (%)	5	15	30	45
Smartphone usage (%)	0	10	35	60
Renewable energy investment (billion USD)	0.1	0.5	1.0	1.5
Carbon capture capacity (Gt CO2/yr)	0	0.1	0.5	1.0
Space exploration budget (billion USD)	0.1	0.2	0.5	1.0
Artificial intelligence research (billion USD)	0.05	0.1	0.3	0.5
Quantum computing investment (billion USD)	0.01	0.05	0.1	0.2
Autonomous vehicle development (billion USD)	0.02	0.1	0.3	0.5
Space exploration budget (billion USD)	0.1	0.2	0.5	1.0
Artificial intelligence research (billion USD)	0.05	0.1	0.3	0.5
Quantum computing investment (billion USD)	0.01	0.05	0.1	0.2
Autonomous vehicle development (billion USD)	0.02	0.1	0.3	0.5

GCG CGA ACT GGT GAA TAT AGT GGC TAC GAC ACG AGT GGT GTG GAG CTC
 A R T G E Y S G Y D T S G V E L>
 _a_a_a_ TRANSLATION OF 27C1 VH.SEQ [A]_a_a_a_a_>

340 * 350 360 *
 * * * *
 TCG GCG CAA GCG ACC ACG GTC ACC GTC TCC TCA
 W G Q G T T V T V S S>
 a TRANSLATION OF 27C1 VH.SEQ [A]_a_a_>

GGCT ATG CAC TGG GTC CGC CAG GCT CCA GCC AAG GGC CTG CAG TGG GTG
A Y H W V R Q P A K G L E W V>
TRANSLATION OF 11E6 VH.SEQ [A]_a_a_a_a_a_>

[illegible][illegible][illegible][illegible]

```

340 *      *      350 *
      GTC TCC TCA AGT GG
      V  S  S  S  G>
      ..TRANSLATION_a_>

```

16

	10	20	30	40
* CAG GTC ACC TTG AAG GAG TCT GGG GGA AGC GTG GTC CAG CCT GGC AGG Q V T L K E S G G S V V Q P G R>				
a a a a a TRANSLATION OF GOLD11-VH [A] a a a a a>				
50 * * * * *	60	70	80	90
TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT AGC TAT S L S C A A S G F T F S S Y>				
a a a a a TRANSLATION OF GOLD11-VH [A] a a a a a>				
100 * * * * *	110	120	130	140
GGC ATG CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG GTG G M H W V R Q A P G K G L E W V>				
a a a a a TRANSLATION OF GOLD11-VH [A] a a a a a>				
150 * * * * *	160	170	180	190
GCA GTT ATA TCA TAT GAT GGA AGT AAT AAA TAC TAT GCA GAC TCC GTG A V I S Y D G S N K Y Y A D S V>				
a a a a a TRANSLATION OF GOLD11-VH [A] a a a a a>				
200 * * * * *	210	220	230	240
AAG GGC CGA TTC ACC ATC TCC AGA GAC AAT TCC AAG AAC ACG CAG TAT K G R F T I S R D N S K N T Q Y>				
a a a a a TRANSLATION OF GOLD11-VH [A] a a a a a>				
250	260	270	280	

* * * * *
 CTG CAA ATG AAC AGC CTG AGA GCT GAA GAC ACG GCA GAG TAT TAC TGT
 L Q M N S L R A E D T A E Y Y C>
 _a_a_a_a_a_TRANSLATION OF GOLD11-VH [A]_a_a_a_a_a_>

290 * * * * * 310 320 330 *
 * * * * *
 GCG AGA ACT GCG GAA TAT AGT GGC CAC GCA TCT ACT GGA GAG AAC GTC
 A R T G E Y S G H A S T G E N V>
 _a_a_a_a_a_TRANSLATION OF GOLD11-VH [A]_a_a_a_a_a_>

340 * * * * * 350 360 *
 * * * * *
 CGG GGC CGG GGC ACC CTG GTC ACC GTC TCG AGT
 W G R G T L V T V S S>
 _a_a_a_a_a_TRANSLATION OF GOLD11-VH [A]_a_a_a_a_a_>

(iv) Gold11-VL

Sequence Range: 1 to 336

10 * * * * * 20 30 40 *
 * * * * *
 TCC TAT GTG CTG ACT CAC CCC CCC TCA GTG TCT GGG ACC CCC GGG CAG
 S Y V L T H P P S V S G T P G Q>
 _a_a_a_a_a_TRANSLATION OF GOLD11-VL [A]_a_a_a_a_a_>

50 * * * * * 60 70 80 90 *
 * * * * *
 AGA GTC ACC ATC TCT TGT TCT GGA GGC AGA TCC AAC ATC GGC AGT AAT
 R V T I S C S G G R S N I G S N>
 _a_a_a_a_a_TRANSLATION OF GOLD11-VL [A]_a_a_a_a_a_>

100 * * * * * 110 120 130 140 *
 * * * * *
 ACT GTA AAG TGG TAT CAG CAG CTC CCA GGA ACG CCC CCC AAA CTC CTC
 T V K W Y Q Q L P G T P P K L L>

a a a TRANSLATION CF GOLD11-VL [A] a a a a

150	160	170	180	190
-----	-----	-----	-----	-----

* * * * *
 ATC TAT GGC CAT GAT CAG CGG CCC TCA GGG ATC CCT GAC CGA TTC TCT
 I Y G N D Q R P S G I P D R F S>
 * * * * *
 TRANSLATION OF GOLD1]-VL [A] a a a a B >

a TRANSLATION OF GOLD11-VL [A]__a__a__a__>

200	210	220	230	240
-----	-----	-----	-----	-----

GGC TCC AAG TCT GGC ACC TCA GCC TCC CTG GCC ATC ACT GGC GTC CAG
G S K S G T S A S L A I T G V Q>

TRANSFORMATION OF GOLD-191

250	260	270	280
-----	-----	-----	-----

[illegible]

A E D E A D Y C Q S Y C S D S M L

1. **Introduction**
 2. **Background**
 3. **Methodology**
 4. **Results**
 5. **Discussion**
 6. **Conclusion**
 7. **References**
 8. **Appendix**
 9. **Index**
 10. **Table of Contents**
 11. **Figure 1**
 12. **Figure 2**
 13. **Figure 3**
 14. **Figure 4**
 15. **Figure 5**
 16. **Figure 6**
 17. **Figure 7**
 18. **Figure 8**
 19. **Figure 9**
 20. **Figure 10**
 21. **Figure 11**
 22. **Figure 12**
 23. **Figure 13**
 24. **Figure 14**
 25. **Figure 15**
 26. **Figure 16**
 27. **Figure 17**
 28. **Figure 18**
 29. **Figure 19**
 30. **Figure 20**
 31. **Figure 21**
 32. **Figure 22**
 33. **Figure 23**
 34. **Figure 24**
 35. **Figure 25**
 36. **Figure 26**
 37. **Figure 27**
 38. **Figure 28**
 39. **Figure 29**
 40. **Figure 30**
 41. **Figure 31**
 42. **Figure 32**
 43. **Figure 33**
 44. **Figure 34**
 45. **Figure 35**
 46. **Figure 36**
 47. **Figure 37**
 48. **Figure 38**
 49. **Figure 39**
 50. **Figure 40**
 51. **Figure 41**
 52. **Figure 42**
 53. **Figure 43**
 54. **Figure 44**
 55. **Figure 45**
 56. **Figure 46**
 57. **Figure 47**
 58. **Figure 48**
 59. **Figure 49**
 60. **Figure 50**
 61. **Figure 51**
 62. **Figure 52**
 63. **Figure 53**
 64. **Figure 54**
 65. **Figure 55**
 66. **Figure 56**
 67. **Figure 57**
 68. **Figure 58**
 69. **Figure 59**
 70. **Figure 60**
 71. **Figure 61**
 72. **Figure 62**
 73. **Figure 63**
 74. **Figure 64**
 75. **Figure 65**
 76. **Figure 66**
 77. **Figure 67**
 78. **Figure 68**
 79. **Figure 69**
 80. **Figure 70**
 81. **Figure 71**
 82. **Figure 72**
 83. **Figure 73**
 84. **Figure 74**
 85. **Figure 75**
 86. **Figure 76**
 87. **Figure 77**
 88. **Figure 78**
 89. **Figure 79**
 90. **Figure 80**
 91. **Figure 81**
 92. **Figure 82**
 93. **Figure 83**
 94. **Figure 84**
 95. **Figure 85**
 96. **Figure 86**
 97. **Figure 87**
 98. **Figure 88**
 99. **Figure 89**
 100. **Figure 90**
 101. **Figure 91**
 102. **Figure 92**
 103. **Figure 93**
 104. **Figure 94**
 105. **Figure 95**
 106. **Figure 96**
 107. **Figure 97**
 108. **Figure 98**
 109. **Figure 99**
 110. **Figure 100**
 111. **Figure 101**
 112. **Figure 102**
 113. **Figure 103**
 114. **Figure 104**
 115. **Figure 105**
 116. **Figure 106**
 117. **Figure 107**
 118. **Figure 108**
 119. **Figure 109**
 120. **Figure 110**
 121. **Figure 111**
 122. **Figure 112**
 123. **Figure 113**
 124. **Figure 114**
 125. **Figure 115**
 126. **Figure 116**
 127. **Figure 117**
 128. **Figure 118**
 129. **Figure 119**
 130. **Figure 120**
 131. **Figure 121**
 132. **Figure 122**
 133. **Figure 123**
 134. **Figure 124**
 135. **Figure 125**
 136. **Figure 126**
 137. **Figure 127**
 138. **Figure 128**
 139. **Figure 129**
 140. **Figure 130**
 141. **Figure 131**
 142. **Figure 132**
 143. **Figure 133**
 144. **Figure 134**
 145. **Figure 135**
 146. **Figure 136**
 147. **Figure 137**
 148. **Figure 138**
 149. **Figure 139**
 150. **Figure 140**
 151. **Figure 141**
 152. **Figure 142**
 153. **Figure 143**
 154. **Figure 144**
 155. **Figure 145**
 156. **Figure 146**
 157. **Figure 147**
 158. **Figure 148**
 159. **Figure 149**
 160. **Figure 150**
 161. **Figure 151**
 162. **Figure 152**
 163. **Figure 153**
 164. **Figure 154**
 165. **Figure 155**
 166. **Figure 156**
 167. **Figure 157**
 168. **Figure 158**
 169. **Figure 159**
 170. **Figure 160**
 171. **Figure 161**
 172. **Figure 162**
 173. **Figure 163**
 174. **Figure 164**
 175. **Figure 165**
 176. **Figure 166**
 177. **Figure 167**
 178. **Figure 168**
 179. **Figure 169**
 180. **Figure 170**
 181. **Figure 171**
 182. **Figure 172**
 183. **Figure 173**
 184. **Figure 174**
 185. **Figure 175**
 186. **Figure 176**
 187. **Figure 177**
 188. **Figure 178**
 189. **Figure 179**
 190. **Figure 180**
 191. **Figure 181**
 192. **Figure 182**
 193. **Figure 183**
 194. **Figure 184**
 195. **Figure 185**
 196. **Figure 186**
 197. **Figure 187**
 198. **Figure 188**
 199. **Figure 189**
 200. **Figure 190**
 201. **Figure 191**
 202. **Figure 192**
 203. **Figure 193**
 204. **Figure 194**
 205. **Figure 195**
 206. **Figure 196**
 207. **Figure 197**
 208. **Figure 198**
 209. **Figure 199**
 210. **Figure 200**
 211. **Figure 201**
 212. **Figure 202**
 213. **Figure 203**
 214. **Figure 204**
 215. **Figure 205**
 216. **Figure 206**
 217. **Figure 207**
 218

[illegible]

B G S R V F G T G T K V T V L G>

a_a_a_a_TRANSLATION OF GOLD11-VL [A]_a_a_a_a_a_>

(v) 1-G2

Sequence Range: 1 to 381

Year	1990	2000	2010
Population (millions)	1.2	1.5	1.8
GDP (billions of dollars)	0.5	1.0	1.5
Life expectancy (years)	55	65	75
Urbanization (%)	30	45	60
Healthcare expenditure (GDP %)	2.5	3.5	4.5
Education expenditure (GDP %)	3.0	4.0	5.0
Infrastructure investment (GDP %)	1.5	2.5	3.5
Government spending (GDP %)	10.0	12.0	14.0
Private sector contribution (GDP %)	15.0	18.0	21.0
Foreign aid (GDP %)	0.5	0.8	1.2
Research and development (GDP %)	0.2	0.5	0.8
Environmental protection (GDP %)	0.1	0.3	0.5
Disaster relief (GDP %)	0.05	0.1	0.2
Space exploration (GDP %)	0.01	0.02	0.05
Art and culture (GDP %)	0.02	0.05	0.1
Religion (GDP %)	0.05	0.1	0.2
Defense (GDP %)	0.5	0.8	1.2
Law enforcement (GDP %)	0.1	0.2	0.3
Public safety (GDP %)	0.05	0.1	0.2
Transportation (GDP %)	0.2	0.4	0.6
Healthcare (GDP %)	0.5	0.8	1.2
Education (GDP %)	0.8	1.2	1.6
Infrastructure (GDP %)	0.3	0.6	0.9
Government (GDP %)	1.0	1.5	2.0
Private sector (GDP %)	1.5	2.0	2.5
Foreign aid (GDP %)	0.1	0.2	0.3
Research and development (GDP %)	0.05	0.1	0.2
Environmental protection (GDP %)	0.02	0.05	0.1
Disaster relief (GDP %)	0.01	0.02	0.05
Space exploration (GDP %)	0.005	0.01	0.02
Art and culture (GDP %)	0.01	0.02	0.05
Religion (GDP %)	0.02	0.05	0.1
Defense (GDP %)	0.1	0.2	0.3
Law enforcement (GDP %)	0.05	0.1	0.2
Public safety (GDP %)	0.02	0.05	0.1
Transportation (GDP %)	0.1	0.2	0.3
Healthcare (GDP %)	0.2	0.4	0.6
Education (GDP %)	0.4	0.6	0.8
Infrastructure (GDP %)	0.1	0.2	0.3
Government (GDP %)	0.5	0.8	1.2
Private sector (GDP %)	0.8	1.2	1.6
Foreign aid (GDP %)	0.05	0.1	0.2
Research and development (GDP %)	0.02	0.05	0.1
Environmental protection (GDP %)	0.01	0.02	0.05
Disaster relief (GDP %)	0.005	0.01	0.02
Space exploration (GDP %)	0.001	0.002	0.005
Art and culture (GDP %)	0.005	0.01	0.02
Religion (GDP %)	0.01	0.02	0.05
Defense (GDP %)	0.05	0.1	0.2
Law enforcement (GDP %)	0.02	0.05	0.1
Public safety (GDP %)	0.01	0.02	0.05
Transportation (GDP %)	0.05	0.1	0.2
Healthcare (GDP %)	0.1	0.2	0.3
Education (GDP %)	0.2	0.4	0.6
Infrastructure (GDP %)	0.05	0.1	0.2
Government (GDP %)	0.2	0.4	0.6
Private sector (GDP %)	0.3	0.5	0.8
Foreign aid (GDP %)	0.02	0.05	0.1
Research and development (GDP %)	0.01	0.02	0.05
Environmental protection (GDP %)	0.005	0.01	0.02
Disaster relief (GDP %)	0.002	0.005	0.01
Space exploration (GDP %)	0.001	0.002	0.005
Art and culture (GDP %)	0.002	0.005	0.01
Religion (GDP %)	0.005	0.01	0.02
Defense (GDP %)	0.02	0.05	0.1
Law enforcement (GDP %)	0.01	0.02	0.05
Public safety (GDP %)	0.005	0.01	0.02
Transportation (GDP %)	0.02	0.05	0.1
Healthcare (GDP %)	0.05	0.1	0.2
Education (GDP %)	0.1	0.2	0.3
Infrastructure (GDP %)	0.02	0.05	0.1
Government (GDP %)	0.1	0.2	0.3
Private sector (GDP %)	0.2	0.4	0.6
Foreign aid (GDP %)	0.01	0.02	0.05
Research and development (GDP %)	0.005	0.01	0.02
Environmental protection (GDP %)	0.002	0.005	0.01
Disaster relief (GDP %)	0.001	0.002	0.005
Space exploration (GDP %)	0.0005	0.001	0.002
Art and culture (GDP %)	0.001	0.002	0.005
Religion (GDP %)	0.002	0.005	0.01
Defense (GDP %)	0.01	0.02	0.05
Law enforcement (GDP %)	0.005	0.01	0.02
Public safety (GDP %)	0.002	0.005	0.01
Transportation (GDP %)	0.01	0.02	0.05
Healthcare (GDP %)	0.02	0	

CAG GTA CAA CCT CAG CAG TCT GGG GGA GAG GTG AAG CAG CCT GGG GCC
Q V Q P Q Q S G E V K Q P G A>

TRANSITION OF I-G2-VH [A]

Year	1970	1975	1980	1985	1990
1970	50	60	70	80	90

* * * * *
 TCC GTG AAG GTT TCC TGT AAG GCG TCT GGA TAC ACC TTC ACC AGC TTC
 S V K V S C K A S G Y T F T S F>
 a a a a TRANSLATION OF 1-G2-VH [A] a a a a a a a a a a
 100 * 110 120 130 140
 * * * * *
 TAT ATG AAC TGG GTG CGA CAG GCC CCC GGA CAA GGG CTT GAG TGG ATG
 Y M N W V R Q A P G Q G L E W M>
 a a a a TRANSLATION OF 1-G2-VH [A] a a a a a a a a a a
 150 160 170 180 190
 * * * * *
 GGA ATA ATC AGC CCT CGT GGT GGT ACG ACA AGT TAC GCA CAG AAC TTC
 G I I S P R G G T T S Y A Q N F>
 a a a a TRANSLATION OF 1-G2-VH [A] a a a a a a a a a a
 200 210 220 230 240
 * * * * *
 CAG GGC AGA GTC ACC ATG ACC AGG GAC ACG TCC ACA AGC ACA GTC TAC
 Q G R V T M T R D T S T S T V Y>
 a a a a TRANSLATION OF 1-G2-VH [A] a a a a a a a a a a
 250 260 270 280
 * * * * *
 ATG GAG CTG AGC AGC CTG AGA TCT GAG GAC ACG GCC GTG TAT TAT TGT
 M E L S S L R S E D T A V Y Y C>
 a a a a TRANSLATION OF 1-G2-VH [A] a a a a a a a a a a
 290 * 300 310 320 330
 * * * * *
 GCG ATA ATT GGG GGT ACT ACT ATG AGA GTA GGG GGG CCC GAT GCT TTT
 A I I G G T T M R V G G P D A F>
 a a a a TRANSLATION OF 1-G2-VH [A] a a a a a a a a a a
 340 * 350 360 370 380
 * * * * *

GAT ATC TGG TGG CAA GGG ACA ATG GTC ACC GTC ACC GTC TCT TCA
 D I W G Q G T M V T V T V S S>
 _a_a_a_TRANSLATION OF 1-G2-VH [A]_a_a_a_a_>

1-H6

Sequence Range: 1 to 381

10 20 30 40
 * * * * *
 GAG GTG CAG CTG GTG GAG TCT GGG GGA GGC GTG GTC CAG CCT GGG AGG
 E V Q L V E S G G V V Q P G R>
 _a_a_a_a_TRANSLATION OF 1-H6 VH [A]_a_a_a_a_>

50 60 70 80 90
 * * * * *
 TCC CTG AGA CTC TCC TGT GCA GCG TCT GGA TTC ACC TTC AGG AAC TAT
 S L R L S C A A S G F T F R N Y>
 _a_a_a_a_TRANSLATION OF 1-H6 VH [A]_a_a_a_a_>

100 110 120 130 140
 * * * * *
 GGC ATG CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG GTG
 G M H W V R Q A P G K G L E W V>
 _a_a_a_a_TRANSLATION OF 1-H6 VH [A]_a_a_a_a_>

150 160 170 180 190
 * * * * *
 GCA GTT ATA TGG TAT GAT GGA AGT AAT AAA TAC TAT GCA GAC TCC GTG
 A V I W Y D G S N K Y Y A D S V>
 _a_a_a_a_TRANSLATION OF 1-H6 VH [A]_a_a_a_a_>

200 210 220 230 240
 * * * * *
 AAG GGC CGA TTC ACC ATC TCC AGA GAC AAT TCC AAG AAC ACG CTG TAT

K G R F T I S R D N S K N T L Y>
 _a_a_a_a_ TRANSLATION OF 1-H6 VH [A] _a_a_a_a_a_>

 * 250 260 270 280
 * * * * *
 CTG CAA ATG AAC ACC CTG AGA GTC GAG GAC ACG GGT GGT TAT TAC TGT
 L Q M N S L R V E D T A V Y Y C>
 _a_a_a_a_a_ TRANSLATION OF 1-H6 VH [A] _a_a_a_a_a_>

 290 300 310 320 330
 * * * * *
 GCG AGA AGA TGG TAT GGT GGC AGT GGT TAT TGG GGC CAC TTC TAC TCC
 A R R W Y C G S G Y W G H F Y S>
 _a_a_a_a_a_ TRANSLATION OF 1-H6 VH [A] _a_a_a_a_a_>

 340 350 360 370 380
 * * * * *
 TAC ATG GAC GGC TGG GGC AAA GGG ACC AAG GTC ACC GTC TCC TCA
 Y M D G W G K G T K V T V S S>
 _a_a_a_a_a_ TRANSLATION OF 1-H6 VH [A] _a_a_a_a_a_>

Figure 2(b) Light chains of antibodies specific for TGFbeta2 isolated following chain shuffling

(i) 6H1 VL

Sequence Range: 1 to 348

10 20 30 40
 * * * * *
 GAT GTT GTG ATG ACT CAG TCT CCA TCC TCC CTG TCT GCA TCT GTA GGA
 D V V M T Q S P S S L S A S V G>
 _a_a_a_a_a_ TRANSLATION OF 6H1 VL SEQ [A] _a_a_a_a_a_>


```

50 *      *      *      *      *      *      *      *
   GAC AGA GTC ACC ATC ACT TGC CGG GCC AGT CAG GGC ATT AGC AAT TAT
   D R V T I T C R A S Q G I S N Y>
   _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A] _a_a_a_a_a_>

100 *      *      *      *      *      *      *      *
   TTA GCC TGG TAT CAG CAA AAA CCA GGG AAA GCC CCT AAG CTC CTG ATC
   L A W Y Q Q K P G K A P K L L I>
   _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A] _a_a_a_a_a_>

150 *      *      *      *      *      *      *      *
   TAT AAG GCA TCT ACT TTA GAA AGT GGG GTC CCA TCA AGG TTC AGT GGC
   Y K A S T L E S G V P S R F S G>
   _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A] _a_a_a_a_a_>

200 *      *      *      *      *      *      *      *
   AGT GGA TCT GGG ACA GAA TTC ACT CTC ACA ATC AGC AGT CTG CAA CCT
   S G S G T E F T L T I S S L Q P>
   _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A] _a_a_a_a_a_>

250 *      *      *      *      *      *      *      *
   GAA GAT TTT GCA ACT TAC TAC TGT CAA CAG AGT TAC AGT ACC CCT CGA
   E D F A T Y Y C Q Q S Y S T P R>
   _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A] _a_a_a_a_a_>

290 *      *      *      *      *      *      *      *
   ACG TTC GGC CAA GGG ACC AAA GTG GAT ATC AAA CGT
   T F G Q G T K V D I K R
   _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A] _a_a_a_a_a_>

```

6A5 VL

Sequence Range: 1 to 327

	10	20	30	40
* TCG TCT GAG CTG ACT CAG GAC CCT GCT GTG TCT GTG GCC TTG GGA CAG				*
S S E L T Q D P A V S V A L G Q>				
a a a TRANSLATION OF 6A5 VL.SEQ [A] a a a a a>				
50	60	70	80	90
* * * * *				*
ACA GTC AGG ATC ACA TGC CAA GGA GAC AGC CTC AGA AGC TAT TAT GGA				*
T V R I C Q G D S L R S Y Y A>				
a a a TRANSLATION OF 6A5 VL.SEQ [A] a a a a a>				
100	110	120	130	140
* * * * *				*
AGC TGG TAC CAG AAG CCA GGA CAG GCC CCT GTA CTT CTC ATC TAT				
S W Y Q Q K P G Q A P V L V I Y>				
a a a TRANSLATION OF 6A5 VL.SEQ [A] a a a a a>				
150	160	170	180	190
* * * * *				*
GGT AAA AAC AAC CGG CCC TCA GGG ATC CCA GAC CGA TTC GCT GGC TCC				
G K N N R P S G I P D R F A G S>				
a a a TRANSLATION OF 6A5 VL.SEQ [A] a a a a a>				
200	210	220	230	240
* * * * *				*
AAC TCA GGA AAC ACA GCT TCC TTG ACC ATC ACT GGG GCT CAG GCG GAG				
N S G N T A S L T I T G A Q A E>				
a a a TRANSLATION OF 6A5 VL.SEQ [A] a a a a a>				
250	260	270	280	
* * * * *				*
GAT GAG GCT GAC TAT TAC TGT AGC TCC CGG GAC AGC AGT GGT AAC CAT				

D E A D Y Y C S S R D S S G N H>
 _a_a_a_ TRANSLATION OF 6A5 VL.SEQ [A] _a_a_a_a_a_>

290 300 310 320
 * * * *
 GTG GTT TTC GGC GGA GGG ACC AAG CTG ACC GTC CTA GGT
 V V F G G G T K L T V L G>
 _a_a_a_ TRANSLATION OF 5A5 VL.SEQ [A] _a_a_a_>

(iv) 5B1 VL

Sequence Range: 1 to 330

10 20 30 40
 * * * *
 TCG TCT GAG CTG ACT CAG GAC CCT GCT GTG TCT GTG GCC TTG GGA CAG
 S S E L T Q D P A V S V A L G Q>
 _a_a_a_ TRANSLATION OF 6B1 VL.SEQ [A] _a_a_a_a_a_>

50 60 70 80 90
 * * * * *
 ACA CTC AGG ATC ACA TGC CAA GGA GAC AGC CTC AGA AGC TAT TAT GCA
 T V R I T C Q G D S L R S Y A>
 _a_a_a_ TRANSLATION OF 6B1 VL.SEQ [A] _a_a_a_a_a_>

100 110 120 130 140
 * * * * *
 AGC TGG TAC CAG CAG AAG CCA GGA CAG GCC CCT GTA CTT GTC ATC TAT
 S W Y Q Q K P G Q A P V L V I Y>
 _a_a_a_ TRANSLATION OF 6B1 VL.SEQ [A] _a_a_a_a_a_>

150 160 170 180 190
 * * * * *
 GGT AAA AAC AAC CGG CCC TCA GGG ATC CCA GAC CGA TTC TCT GGC TCC
 G K N N R P S G I P D R F S G S>
 _a_a_a_ TRANSLATION OF 6B1 VL.SEQ [A] _a_a_a_a_a_>

(v) 11E6 VL

Sequence Range: 1 to 324

[illegible][illegible]

CGA GGG GTG TTC GGC GGA GGG ACC AAG CTG ACC GTC CTA GGT
R G V F G G T K L T V L G>
TRANSLATION OF 6B1 VL SEQ [A]—a—a—a—>

	10	20	30	40
GAA GTT GTG CTG ACT CAG TCT CCA TCC CTC TCT GCA TCT GTA GGA	*	*	*	*
E V V L T Q S P S S L S A S V G>	a	a	a	a

	50	*	* * *	60	*	*	70	*	*	80	*	90	*
GAC	AGA	GTC	ACC	ATC	ACT	TGC	CGG	GCA	AGT	CAG	GGC	ATT	CGA
D R V T I T C R A S Q G I G D >	a e a	a	a	a	a	a	a	a	a	a	a	a	a
TRANSLATION OF 11E6 VL SEQ [A] a a a a a a a													

```

* * * * *
TTG GGC TGG TAT CAG CAG AAG CCA GGG AAA GCC CCT ATC CTC CTG ATC
L G W Y Q Q K P G K A P I L L I>
_a_a_a_ TRANSLATION OF 11E6 VL.SEQ [A]_a_a_a_a_a_>

150 160 170 180 190
* * * * *
TAT GGT ACA TCC ACT TTA CAA AGT GGG GTC CCG TCA AGG TTC AGC GGC
Y G T S T L Q S G V P S R F S G>
_a_a_a_ TRANSLATION OF 11E6 VL.SEQ [A]_a_a_a_a_a_>

200 210 220 230 240
* * * * *
AGT GGA TCT GGC ACA GAT TTC ACT CTC ACC ATC AAC AGC CTG CAG CCT
S G S G T D F T L T I N S L Q P>
_a_a_a_ TRANSLATION OF 11E6 VL.SEQ [A]_a_a_a_a_a_>

250 260 270 280
* * * * *
GAA GAT TTT GCA ACT TAT TAC TGT CTA CAA GAT TCC AAT TAC CCG CTC
E D F A T Y Y C L Q D S N Y P L>
_a_a_a_ TRANSLATION OF 11E6 VL.SEQ [A]_a_a_a_a_a_>

290 300 310 320
* * * * *
ACT TTC GGC GGA GGG ACA CGA CTG GAG ATT AAA CGT
T F G G G T R L E I K R>
_a_a_a_ TRANSLATION OF 11E6 VL.SEQ [A]_a_a_a_a_a_>

```

(v) 14F12 VL

Sequence Range: 1 to 321

```

10 20 30 40
* * * * *
TCG TCF GAG CTG ACT CAG GAC CCT GCT GTG TCT GTG GCC TTG GGA CAG

```

TTC GGC GGA CGG ACC AAG CTG ACC GTG CTA GGT
 *
 290 * 300 * 310 * 320 *

___a___TRANSLATION OF 14P12 VL SEQ [A]___a___>

Figure 3 Sequence of VH CDR3 of spiked clones derived from 1B2

PARENT (1-B2)	A R T G E Y S G Y D S S G V D V W
27-C1	A R T G E Y S G Y D T S G V E L W
27-D7	A R T R E Y S G H D S S G V D D W
27-E10	A R T G P F S G Y D S S G E D V R
27-H1	A R T E E Y S G Y D S S G V D V W
27-E2	A Q T R E Y T G Y D S S G V D V W
28-A11	A R T E E Y S G F D S T G E D V W
28-E12	A R T E E F S G Y D S S G V D V W
28-H10	A R T G E Y S G Y H S S G V D V R
31-G2	A R T E E F S G Y D S S G V D V W
30-B6	A R A G P F S G Y D S S G E D V R
30-E9	A R T G P F S G Y D S S G E D V W
30-F6	A R T E E F S G Y D S S G V D V W
30-D2	A R T G E Y S G Y D S S G E L V W
31-A2	A R T E E F S G Y D S T G E E V W
31-E11	A R T E E F S G Y D S S G V D V W
31-F1	A R T G E Y S G Y D S S G E D V W

Differences from 1B2 VH CDR3 are in bold.

Sequence Range: 1 to 327


	10	20	30	40
* * *	*	*	*	*
TCC TCT GAG CTG ACT CAG GAC CCT GCT GTG TCT GTG GCC TTG GGA CAG				
S S E L T Q D P A V S V A L G Q>				
a a a a TRANSLATION OF VT37-VL [A]	a	a	a	a
>				
	50	60	70	80
90				
* * *	*	*	*	*
ACA GTT AGG ATC ACT TCC CAA GGA GAC AGT CTC AGA AGC TAT TAC ACA				
T V R I T S Q G D S L R S Y Y T>				
a a a a TRANSLATION OF VT37-VL [A]	a	a	a	a
>				
	100	110	120	130
140				
* * *	*	*	*	*
AAC TGG TTT CAG CAG AAG CCA GGA CAG CCC CCT CTA CTT GTC GTC TAT				
N W F Q Q K P G Q P P L L V V Y>				
a a a a TRANSLATION OF VT37-VL [A]	a	a	a	a
>				
	150	160	170	180
190				
* * *	*	*	*	*
GCT AAA AAT AAG CGG CCC TCA GGG ATC CCA GAC CGA TTC TCT GGC TCC				
A K N K R P S G I P D R F S G S>				
a a a a TRANSLATION OF VT37-VL [A]	a	a	a	a
>				
	200	210	220	230
240				
+ * *	*	*	*	*
AGC TCA GGA AAC ACA GCT TCC TTG ACC ATC ACT GGG GCT CAG GCG GAA				
S S G N T A S L T I T G A Q A E>				
a a a a TRANSLATION OF VT37-VL [A]	a	a	a	a
>				
	250	260	270	280
* * *	*	*	*	*
GAT GAG GCT GAC TAT TAC TGT CAT TCC CGG GAC AGC AGT GGT AAC CAT				

D E A D Y Y C H S R D S S G N H>
 a a a a TRANSLATION OF VT37-VL [A] a a a a a a
 290 * 300 310 320 *
 GTG CTT TTC GGC GGA GGG ACC AAG CTG ACC GTC CTA GGT
 V L F G G C T K L T V L G>
 a a TRANSLATION OF VT37-VL [A] a a a a a a>

Figure 6 pG4D100

Map

MAP OF pG4D100 (NOT TO SCALE)



MCS: 5' HindIII - PacI - BamHI - (XhoI) - (PmlI) - (NheI) - AscI -
 (BssHII) - XhoI - PmeI - BsiWI 3'

NOTE: THOSE R. SITES SHOWN IN BRACKETS ARE NOT UNIQUE.

Figure 7

v1cassetteCAT1

DNA coding for v1 leader including intren. ApaLI site in the leader

With 5 enzymes: HindIII SacI ApaLI XhoI BamHI

June 16, 1994 15:44 ..

```

H
i
n
d
I
I
I
I
aagcttcgccaccatgggatggagctgtatcatcctctctcttggtagcaacagctacagg
1 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 60
ttcgaaagcgggtggtaccctacctcgacatagtaggagaagaaccatcgttctcgatgtcc

      M G W S C I I L F L V A T A T

taaggggctcaacagtacaggttgaggtetggacatatatatgggtgacaatgacatcc
61 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 120
attccccgagtgctcatcgtccgaactccagacctgtatatatacccactgttactgtagg

      A                               S
      P                               a
      a                               c
      L                               c
      I                               I

actttgctttctctctccacaggtgtgcactccgacattgagctcacccagctctccagaca
121 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 180
tgaaacggaaagagaggtgtccacacgtgaggctgttaactcgagtggtggaagaggtctgt

      G V K S D I E L

      X                               B
      h                               a
      o                               m
      I                               K
      I                               I

aagctcgagctgaaacgtgagtagaatttaaactttgcttccctcaattggatcc
181 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 234
ttcgagctcgactttgcactcatcttaaatttgaaacgaaggagtttaacctagg

      L E L K

```

Enzymes that do cut:

ApaLI BamHI HindIII SacI XhoI


Enzymes that do not cut:

NONE

Figure 8 pLN10

Map

MAP OF pLN10 (NOT TO SCALE)



MULTIPLE CLONING SITE (MCS):

^{5'} Hind III - (Sph I) - (Pst I) - Sal I - Xba I - Bam HI ^{3'}


1224 1259

NOTE: RESTRICTION SITES IN BRACKETS ARE NOT UNIQUE.

Figure 9 pKN100

Map

MAP OF pKN100 (NOT TO SCALE)



MCS: 5' MLuI - (AvaI) - HindIII - (SphI) - (PstI) - SalI - XbaI - BamHI 3'





Fig 11 Neutralisation of TGF β 2 by Whole IgG4 Antibodies

Figure 12.
Scatter plots of individual animal data points. Bar graph is the mean of the group.






Fig. 13(a)



- | | |
|---------------------------------------|-------------------------|
| 1 interleukin 1 | 11 GADPH |
| 2 human lymphotoxin (TNFbeta) | 12 ovalbumin |
| 3 human insulin | 13 hen egg lysozyme |
| 4 human serum albumin | 14 bovine serum albumin |
| 5 ss DNA | 15 TNF-alpha |
| 6 oxazolone-bovine serum albumin | 16 TGF beta 1 |
| 7 keyhole limpet haemocyanin | 17 TGF beta 2 |
| 8 chicken egg white trypsin inhibitor | 18 TGF beta 3 |
| 9 chymotrypsinogen | 19 PBS only |
| 10 cytochrome c | |

Fig. 13 (b)



For both Fig 13 (a) + (b). Antigens 1 to 15 were used for coating the plate at a concentration of $10 \mu\text{g/ml}$ in PBS. The TGFβ's were coated at $0.2 \mu\text{g/ml}$ in PBS. Coating was performed at 4°C overnight.

$100 \mu\text{l}$ of each antigen was used per well and duplicates of each antigen for each IgG to be tested. IgG samples were incubated with the coated antigens at 37°C for 2 hours after blocking with 2% marvel-PBS. The labelled second antibody was a mouse anti-human Fc, alkaline phosphatase conjugated and the substrate used to detect bound second antibody was PNPP at 1mg/ml with the absorbance read at 405nm .

FIGURE 14





FIGURE 15



NEUTRALISATION OF TGF BETA 2 ANTI-PROLIFERATIVE EFFECT
ON TF1 CELLS BY WHOLE ANTIBODIES




Figure 16

TGF BETA I




Figure 17




Figure 18

2A-HL: VH (also known as 6H2 VH)

Sequence Range: 1 to 345

```

      *          10      20      30      40      *
GAG GTG CAG CTG GAG TCT GGG GGA GCC GTG GTC CAG CCT GGG AGG *
E V Q L V E S G G G V V Q P G R>
_a _a _a TRANSLATION OF 6H1 VH.SEQ [A] _a _a _a _a >

50      *          60      70      80      90      *
TCC CTG AGA CTC TCC TGT GCA GCG TCT GGA TTC ACC TTC AGT AGC TAT *
S L R L S C A A S G F T F S S Y>
_a _a _a TRANSLATION OF 6H1 VH.SEQ [A] _a _a _a _a >

100     *          110     120     130     140     *
GGC ATG CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG GTG
G M H W V R Q A P G K G L E W V>
_a _a _a TRANSLATION OF 6H1 VH.SEQ [A] _a _a _a _a >

150     *          160     170     180     190     *
GCA GTT ATA TGG TAT GAT GGA AGT AAT AAA TAC TAT GCA GAC TCC GTG
A V I W Y D G S N K Y Y A D S V>
_a _a _a TRANSLATION OF 6H1 VH.SEQ [A] _a _a _a _a >

200     *          210     220     230     240     *
AAG GGC CGA TTC ACC ATC TCC AGA GAC AAT TCC AAG AAC ACG CTG TAT *
K G R F T I S R D N S K N T L Y>
_a _a _a TRANSLATION OF 6H1 VH.SEQ [A] _a _a _a _a >

```

250 * * * * * 260 * * * * * 270 * * * * * 280 * * * * *
 CTG CAA ATG GAC AGC CTG AGA GCC GAG GAC AGC GCC GGC GTG TAT TAC TGT
 L Q M D S L R A E D T A V Y Y C>
 _a_a_e_ TRANSLATION OF 6H1 VH.SEQ [A]_a_a_a_a_a_>
 290 * * * * * 300 * * * * * 310 * * * * * 320 * * * * * 330 * * * * *
 GGA AGA ACC CTG GAG TCT AGT TTG TGG GCC CAA GGC ACC CTG GTC ACC
 G R T L E S S L W G Q G T L V T>
 _a_a_a_ TRANSLATION OF 6H1 VH.SEQ [A]_a_a_a_a_a_>

340

*
 GTC TCC TCA
 V S S>
 _a_e_>

6B1 VL

Sequence Range: 1 to 330

10 * * * * * 20 * * * * * 30 * * * * * 40 * * * * *
 TCG TCT GAG CTG ACT CAG GAC CCT GCT GTG TCT GTG GCC TTG GGA CAG
 S S E L T Q D P A V S V A L G Q>
 _a_a_a_ TRANSLATION OF 6B1 VL.SEQ [A]_a_a_a_a_a_>
 50 * * * * * 60 * * * * * 70 * * * * * 80 * * * * * 90 * * * * *
 ACA GTC AGG ATC ACA TGC CAA GGA GAC AGC CTC AGA AGC TAT TAT GCA
 T V R I T C Q G D S L R S Y Y A>
 _a_a_a_ TRANSLATION OF 6B1 VL.SEQ [A]_a_a_a_a_a_>

```

100 *      *      *      *      *      *      *      *      *      *
    AGC TGG TAC CAG CAG AAG CCA GGA CAG GCC CCT GTA CTT GTC ATC TAT
    S W Y Q Q K P G Q A P V L V I Y>
    _a_a_a_ TRANSLATION OF 6B1 VL.SEQ [A]_a_a_a_a_a_>

150 *      *      *      *      *      *      *      *      *      *
    GGT AAA AAC AAC CGG CCC TCA GGG ATC CCA GAC CGA TTC TCT GGC TCC
    G K N N R P S G I P D R F S G S>
    _a_a_a_ TRANSLATION OF 6B1 VL.SEQ [A]_a_a_a_a_a_>

200 *      *      *      *      *      *      *      *      *      *
    AGC TCA GGA AAC ACA GCT TCC TTG ACC ATC ACT GGG GCT CAG GCG GAA
    S S G N T A S L T I T G A Q A E>
    _a_a_a_ TRANSLATION OF 6B1 VL.SEQ [A]_a_a_a_a_a_>

250 *      *      *      *      *      *      *      *      *      *
    GAT GAG GCT GAC TAT TAC TGT AAC TCC CGG GAC AGC AGT AGT ACC CAT
    D E A D Y Y C N S R D S S S T H>
    _a_a_a_ TRANSLATION OF 6B1 VL.SEQ [A]_a_a_a_a_a_>

290 *      *      *      *      *      *      *      *      *      *
    CGA GGG GTG TTC GGC GGA GGG ACC AAG CTG ACC GTC CTA GGT
    R G V F G G G T K L T V L G>
    _a_a_a_ TRANSLATION OF 6B1 VL.SEQ [A]_a_a_a_a_a_>

```

625 VL

Sequence Range: 1 to 327

[illegible]

250 * 260 270 280
 GAT GAG GGT GAC TAT TAC TGT AGC TCC CGG GAC AGC AGT GGT AAC CAT
 D E A D Y Y C S S R D S S G N H>
 _a_a_a_ TRANSLATION OF 6A5 VL.SEQ [A] _a_a_a_a_>
 290 * 300 310 320
 GTG GTT TTC GGC GGA GGG ACC AAG CTG ACC CTC CTA GGT
 V V F G G G T K L T V L G>
 _a_a_a_ TRANSLATION OF 6A5 VL.SEQ [A] _a_a_a_>

6H1 VL

Sequence Range: 1 to 348

10 20 30 40
 * * * *
 GAT GTT GTG ATG ACT CAG TCT CCA TCC TCC CTG TCT GCA TCT GTA GGA
 D V V M T Q S P S S L S A S V G>
 _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A] _a_a_a_a_>
 50 60 70 80 90
 * * * * *
 GAC ACA GTC ACC ATC ACT TGC CGG GCC AGT CAG GGC ATT AGC AAT TAT
 D R V T I T C R A S Q G I S N Y>
 _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A] _a_a_a_a_>
 100 110 120 130 140
 * * * * *
 TTA GCC TGG TAT CAG CAA AAA CCA GGG AAA GCC CCT AAG CTC CTG ATC
 L A W Y Q Q K P G K A P K L L I>
 _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A] _a_a_a_a_>

150 * 160 170 180 190
 TAT AAG GCA TCT ACT TTA GAA AGT GGG GTC CCA TCA AGG TTC AGT GGC
 Y K A S T L E S G V P S R F S G>
 _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A]_a_a_a_a_a_>

 200 210 220 230 240
 * * * * *
 AGT GGA TCT GGG ACA GAA TTC ACT CTC ACA ATC AGC AGT CTG CAA CCT
 S G S G T E F T L T I S S L Q P>
 _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A]_a_a_a_a_a_>

 250 260 270 280
 + * * * *
 GAA GAT TTT GCA ACT TAC TAC TGT CAA CAG AGT TAC AGT ACC CCT CGA
 E D F A T Y Y C Q Q S Y S T P R>
 _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A]_a_a_a_a_a_>

 290 300 310 320 330
 * * * * *
 ACG TTC GGC CAA GGG ACC AAA GTG GAT ATC AAA CGT
 T F G Q G T K V D I K R
 _a_a_a_ TRANSLATION OF 6H1 VL.SEQ [A]_a_a_a_a_a_>